RICO Audrey
Research Projects
Publications :
180164
RICO
1
harvard-cite-them-right-no-et-al
50
date
desc
year
2625
https://crmbm.univ-amu.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A50%2C%22request_next%22%3A50%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22C2999DIC%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Stellmann%20et%20al.%22%2C%22parsedDate%22%3A%222025-11-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BStellmann%2C%20J.-P.%2C%20Maarouf%2C%20A.%2C%20Nicolescu%2C%20M.%2C%20Boutiere%2C%20C.%2C%20Rico%2C%20A.%2C%20Zaaraoui%2C%20W.%2C%20Guye%2C%20M.%2C%20Pelletier%2C%20J.%2C%20Ranjeva%2C%20J.-P.%20and%20Audoin%2C%20B.%20%282025%29%20%26%23x201C%3BEarly%20structural%20hub%20disruption%20leads%20to%20premature%20functional%20adaption%20in%20multiple%20sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BBrain%20Structure%20%26amp%3B%20Function%26lt%3B%5C%2Fi%26gt%3B%2C%20230%289%29%2C%20p.%20172.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00429-025-03023-2%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00429-025-03023-2%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Early%20structural%20hub%20disruption%20leads%20to%20premature%20functional%20adaption%20in%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Patrick%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mihaela%22%2C%22lastName%22%3A%22Nicolescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wafaa%22%2C%22lastName%22%3A%22Zaaraoui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Phillipe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22In%20Multiple%20Sclerosis%2C%20inflammation%20and%20neurodegeneration%20disrupt%20structural%20and%20functional%20brain%20networks.%20While%20the%20association%20between%20structural%20connectivity%20and%20disability%20is%20rather%20clear%2C%20functional%20connectivity%20changes%20are%20not%20yet%20characterised%20as%20a%20physiological%20response%20to%20the%20disease%2C%20as%20functionally%20meaningful%20adaptation%20or%20as%20a%20deceptive%20response.%20We%20explored%20the%20topology%20of%20brain%20networks%20of%2065%20Multiple%20Sclerosis%20patients%20over%20up%20to%20seven%20years%20in%20comparison%20to%2059%20controls.%20Connectomes%20based%20on%20probabilistic%20tractography%20from%20diffusion%20weighted%20imaging%20and%20resting-state%20MRI%2C%20were%20analysed%20with%20graph%20theory.%20The%20hub%20disruption%20index%20estimated%20connectivity%20perturbation%20in%20relation%20to%20the%20network%20hierarchy.%20In%20controls%2C%20we%20observed%20a%20transient%20increase%20in%20functional%20hub%20connectivity%20in%20the%205th%20and%206th%20age%20decade%20as%20a%20response%20to%20a%20subtle%20diffuse%20loss%20of%20structural%20connectivity%2C%20before%20structural%20and%20functional%20connectomes%20show%20a%20pronounced%20loss%20of%20hub%20connectivity.%20In%20Multiple%20Sclerosis%2C%20structural%20hub%20disruption%20was%20present%20from%20the%20disease%20onset%20while%20the%20transient%20upregulation%20of%20functional%20hub%20connectivity%20in%20the%20middle%20age%20was%20lacking.%20Patients%20seem%20to%20transition%20directly%20into%20an%20exhausted%20hub%20connectivity%20configuration.%20However%2C%20we%20observed%20the%20transient%20functional%20reorganisation%20of%20hubs%20in%20the%20first%20years%20after%20disease%20onset.%20Multiple%20Sclerosis%20patients%20present%20a%20probable%20physiological%20response%20to%20structural%20connectivity%20loss%20very%20early%20in%20the%20disease%2C%20potentially%20leading%20to%20an%20accelerated%20hub%20overload%20with%20accelerated%20neurodegeneration.%20The%20onset%20of%20chronic%20progression%20in%20the%205th%20age%20decade%20might%20be%20partially%20driven%20by%20the%20absence%20of%20the%20physiological%20increased%20hub%20connectivity%20observed%20in%20healthy%20individuals.%22%2C%22date%22%3A%222025-11-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00429-025-03023-2%22%2C%22ISSN%22%3A%221863-2661%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22UP3H3ICX%22%2C%22B4EWFM7E%22%2C%229L2KHJ5X%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222025-11-06T15%3A36%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22JITMD4XG%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Demortiere%20et%20al.%22%2C%22parsedDate%22%3A%222025-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDemortiere%2C%20S.%2C%20Stolowy%2C%20N.%2C%20Perriguey%2C%20M.%2C%20Boutiere%2C%20C.%2C%20Rico%2C%20A.%2C%20Hilezian%2C%20F.%2C%20Ndjomo-Ndjomo%2C%20B.-R.%2C%20Durozard%2C%20P.%2C%20Stellmann%2C%20J.-P.%2C%20Marignier%2C%20R.%2C%20Boucraut%2C%20J.%2C%20Pelletier%2C%20J.%2C%20Maarouf%2C%20A.%20and%20Audoin%2C%20B.%20%282025%29%20%26%23x201C%3BDiagnostic%20Utility%20of%20Kappa%20Free%20Light%20Chain%20Index%20in%20Adults%20With%20Inaugural%20Optic%20Neuritis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2C%2012%283%29%2C%20p.%20e200386.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200386%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200386%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Diagnostic%20Utility%20of%20Kappa%20Free%20Light%20Chain%20Index%20in%20Adults%20With%20Inaugural%20Optic%20Neuritis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natacha%22%2C%22lastName%22%3A%22Stolowy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Perriguey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Blaise-Roger%22%2C%22lastName%22%3A%22Ndjomo-Ndjomo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Patrick%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%22%2C%22lastName%22%3A%22Boucraut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20A%20simple%2C%20quick%2C%20and%20reproducible%20procedure%20for%20distinguishing%20multiple%20sclerosis%20%28MS%29%2C%20myelin%20oligodendrocyte%20glycoprotein%20antibody-associated%20disease%20%28MOGAD%29%2C%20and%20neuromyelitis%20optica%20spectrum%20disorder%20%28NMOSD%29%20at%20inaugural%20optic%20neuritis%20%28ION%29%20could%20be%20highly%20valuable%20in%20guiding%20early%20management.%5CnMETHODS%3A%20We%20included%20all%20adults%20admitted%20to%20the%20MS%20center%20of%20Marseille%20for%20ION%20between%20March%202016%20and%20April%202024%2C%20with%20CSF%20analysis%20including%20the%20kappa%20free%20light%20chain%20%28K-FLC%29%20index.%20Receiver%20operating%20characteristic%20curves%20were%20used%20to%20measure%20the%20diagnostic%20ability%20of%20the%20K-FLC%20index.%5CnRESULTS%3A%20Two%20hundred%20twenty-seven%20adults%20were%20admitted%20for%20ION%3B%20210%20%2893%25%29%20had%20a%20K-FLC%20index%20measurement.%20MS%20was%20diagnosed%20in%2084%20%2840%25%29%3B%20clinically%20isolated%20syndrome%20suggestive%20of%20MS%20in%2077%20%2836.5%25%29%2C%20including%2020%20with%20future%20conversion%20to%20MS%20%28CISwc%29%3B%20MOGAD%20in%2026%20%2812.5%25%29%3B%20NMOSD%20in%2013%20%286%25%29%3B%20and%20other%20inflammatory%20disorders%20in%2010%20%285%25%29.%20A%20K-FLC%20index%20%5Cu22656.7%20differentiated%20MS%5C%2FCISwc%20from%20other%20diagnoses%20with%20specificity%2086%25%20and%20sensitivity%2095%25%20%28area%20under%20the%20curve%20%5BAUC%5D%200.94%29.%20A%20K-FLC%20index%20%26lt%3B4.9%20differentiated%20MOGAD%20from%20other%20diagnoses%20with%20specificity%2063%25%20and%20sensitivity%2092%25%20%28AUC%200.78%29%20and%20MOGAD%20from%20MS%5C%2FCISwc%20with%20specificity%2096%25%20and%20sensitivity%2092%25%20%28AUC%200.97%29.%20Among%20all%20patients%2C%2093%20%2844%25%29%20had%20a%20K-FLC%20index%20%26lt%3B4.9%3A%2024%20of%20these%20%2826%25%29%20had%20MOGAD%20and%205%20%285.5%25%29%20MS%5C%2FCISwc.%20Among%20the%20remaining%20patients%20with%20a%20K-FLC%20index%20%5Cu22654.9%20%28n%20%3D%20117%29%2C%202%20%281.7%25%29%20had%20MOGAD%20%28K-FLC%20index%20of%207.9%20and%2016.2%29%20and%2099%20%2885%25%29%20MS%5C%2FCISwc.%20Among%20patients%20with%20normal%20MRI%20%28n%20%3D%2096%29%2C%2073%20%2876%25%29%20had%20a%20K-FLC%20index%20%26lt%3B4.9%3A%2022%20of%20these%20%2830%25%29%20had%20MOGAD%2C%20and%20none%20showed%20conversion%20to%20MS.%20Among%20the%20remaining%20patients%20with%20a%20K-FLC%20index%20%5Cu22654.9%20%28n%20%3D%2023%29%2C%202%20%288.5%25%29%20had%20MOGAD%20and%207%20%2830.5%25%29%20showed%20conversion%20to%20MS.%20The%20K-FLC%20index%20did%20not%20differentiate%20NMOSD%20from%20other%20diagnoses%20and%20only%20moderately%20differentiated%20NMO%20from%20MS%5C%2FCISwc%20%28AUC%200.80%29.%5CnDISCUSSION%3A%20The%20K-FLC%20index%20is%20an%20accessible%20biomarker%20to%20guide%20early%20diagnosis%20in%20patients%20with%20ION.%20The%20probability%20of%20MOGAD%20in%20patients%20with%20ION%20and%20a%20K-FLC%20index%20%5Cu22654.9%20is%20low%20even%20in%20case%20of%20normal%20brain%5C%2Fspinal%20cord%20MRI.%5CnCLASSIFICATION%20OF%20EVIDENCE%3A%20This%20study%20provides%20Class%20II%20evidence%20that%20for%20patients%20with%20ION%2C%20the%20K-FLC%20index%20can%20distinguish%20between%20MS%5C%2FCISwc%20and%20MOGAD.%22%2C%22date%22%3A%222025-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000200386%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%2C%229L2KHJ5X%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A07Z%22%7D%7D%2C%7B%22key%22%3A%22J9GHBINL%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guttieres%20et%20al.%22%2C%22parsedDate%22%3A%222025-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGuttieres%2C%20L.%2C%20Vannelli%2C%20L.%2C%20Demortiere%2C%20S.%2C%20Perriguey%2C%20M.%2C%20Elziere%2C%20M.%2C%20Durozard%2C%20P.%2C%20Boutiere%2C%20C.%2C%20Rico%2C%20A.%2C%20Hilezian%2C%20F.%2C%20Stellmann%2C%20J.-P.%2C%20Pelletier%2C%20J.%2C%20Maarouf%2C%20A.%2C%20Stolowy%2C%20N.%20and%20Audoin%2C%20B.%20%282025%29%20%26%23x201C%3BFluorescein%20Angiography%20as%20a%20Surrogate%20Marker%20of%20Disease%20Activity%20in%20Susac%20Syndrome%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2C%2012%282%29%2C%20p.%20e200379.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200379%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200379%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Fluorescein%20Angiography%20as%20a%20Surrogate%20Marker%20of%20Disease%20Activity%20in%20Susac%20Syndrome%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Guttieres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lea%22%2C%22lastName%22%3A%22Vannelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Perriguey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maya%22%2C%22lastName%22%3A%22Elziere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Patrick%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natacha%22%2C%22lastName%22%3A%22Stolowy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20To%20evaluate%20the%20sensitivity%20of%20fluorescein%20angiography%20%28FA%29%20in%20detecting%20disease%20activity%20in%20Susac%20syndrome.%5CnMETHODS%3A%20We%20conducted%20a%20blinded%20analysis%20of%20all%20FA%2C%20brain%20MRI%2C%20and%20audiogram%20examinations%20performed%20throughout%20the%20follow-up%20of%20patients%20with%20Susac%20syndrome.%5CnRESULTS%3A%20A%20total%20of%2079%20FA%20examinations%2C%2085%20brain%20MRI%20scans%2C%20and%2049%20audiograms%20were%20analyzed%20from%209%20patients%20followed%20for%20a%20mean%20%28SD%29%20period%20of%206%20%284%29%20years.%20Disease%20activity%20was%20detected%20in%2041.5%25%20of%20FA%20examinations%2C%2010.5%25%20of%20MRI%20scans%2C%20and%2025%25%20of%20audiograms%20%28FA%20vs%20MRI%2C%20p%20%26lt%3B%200.0001%3B%20FA%20vs%20audiogram%2C%20p%20%3D%200.06%3B%20audiogram%20vs%20MRI%2C%20p%20%26lt%3B%200.05%29.%20Within%203%20months%20of%20clinical%20relapses%2C%20activity%20was%20observed%20in%2057%25%2C%2024%25%2C%20and%2027%25%20of%20FA%2C%20MRI%2C%20and%20audiogram%20examinations%2C%20respectively%20%28FA%20vs%20MRI%2C%20p%20%26lt%3B%200.05%3B%20FA%20vs%20audiogram%2C%20p%20%3D%200.09%3B%20audiogram%20vs%20MRI%2C%20p%20%3D%201%29.%20Quantitative%20analysis%20of%20FA%20showed%20a%20mean%20%28SD%29%20of%202.5%20%282.5%29%20leakages%20%28both%20eyes%29%20during%20relapses%20compared%20with%201.2%20%281.4%29%20during%20remission%20%28p%20%26lt%3B%200.05%29.%5CnDISCUSSION%3A%20FA%2C%20particularly%20arterial%20leakage%2C%20demonstrated%20the%20highest%20sensitivity%20in%20detecting%20disease%20activity%20and%20may%20be%20a%20valuable%20tool%20for%20treatment%20management%20in%20Susac%20syndrome.%20Future%20studies%20with%20larger%20samples%20should%20aim%20to%20identify%20the%20optimal%20threshold%20of%20FA%20changes%20associated%20with%20an%20increased%20risk%20of%20relapse.%22%2C%22date%22%3A%222025-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000200379%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%2C%229L2KHJ5X%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A29Z%22%7D%7D%2C%7B%22key%22%3A%22CHX847WV%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Durozard%20et%20al.%22%2C%22parsedDate%22%3A%222024-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDurozard%2C%20P.%2C%20Maarouf%2C%20A.%2C%20Zaaraoui%2C%20W.%2C%20Stellmann%2C%20J.-P.%2C%20Bouti%26%23xE8%3Bre%2C%20C.%2C%20Rico%2C%20A.%2C%20Demorti%26%23xE8%3Bre%2C%20S.%2C%20Guye%2C%20M.%2C%20Le%20Troter%2C%20A.%2C%20Dary%2C%20H.%2C%20Ranjeva%2C%20J.-P.%2C%20Audoin%2C%20B.%20and%20Pelletier%2C%20J.%20%282024%29%20%26%23x201C%3BCortical%20Lesions%20as%20an%20Early%20Hallmark%20of%20Multiple%20Sclerosis%3A%20Visualization%20by%207%20T%20MRI%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BInvestigative%20Radiology%26lt%3B%5C%2Fi%26gt%3B%2C%2059%2811%29%2C%20p.%20747.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FRLI.0000000000001082%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FRLI.0000000000001082%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cortical%20Lesions%20as%20an%20Early%20Hallmark%20of%20Multiple%20Sclerosis%3A%20Visualization%20by%207%20T%20MRI%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wafaa%22%2C%22lastName%22%3A%22Zaaraoui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Patrick%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Bouti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demorti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Le%20Troter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Dary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%5D%2C%22abstractNote%22%3A%22Objectives%5Cu00a0%5Cn%20%20%20%20%20%20%20%20%20%20Compelling%20evidence%20indicates%20a%20significant%20involvement%20of%20cortical%20lesions%20in%20the%20progressive%20phase%20of%20multiple%20sclerosis%20%28MS%29%2C%20significantly%20contributing%20to%20late-stage%20disability.%20Despite%20the%20promise%20of%20ultra-high-field%20magnetic%20resonance%20imaging%20%28MRI%29%20in%20detecting%20cortical%20lesions%2C%20current%20evidence%20falls%20short%20in%20providing%20insights%20into%20the%20existence%20of%20such%20lesions%20during%20the%20early%20stages%20of%20MS%20or%20their%20underlying%20cause.%20This%20study%20delineated%2C%20at%20the%20early%20stage%20of%20MS%2C%20%281%29%20the%20prevalence%20and%20spatial%20distribution%20of%20cortical%20lesions%20identified%20by%207%20T%20MRI%2C%20%282%29%20their%20relationship%20with%20white%20matter%20lesions%2C%20and%20%283%29%20their%20clinical%20implications.%5Cn%20%20%20%20%20%20%20%20%20%20Materials%20and%20Methods%5Cu00a0%5Cn%20%20%20%20%20%20%20%20%20%20Twenty%20individuals%20with%20early-stage%20relapsing-remitting%20MS%20%28disease%20duration%20%26lt%3B1%20year%29%20underwent%20a%207%20T%20MRI%20session%20involving%20T1-weighted%20MP2RAGE%2C%20T2%2A-weighted%20multiGRE%2C%20and%20T2-weighted%20FLAIR%20sequences%20for%20cortical%20and%20white%20matter%20segmentation.%20Disability%20assessments%20included%20the%20Expanded%20Disability%20Status%20Scale%2C%20the%20Multiple%20Sclerosis%20Functional%20Composite%2C%20and%20an%20extensive%20evaluation%20of%20cognitive%20function.%5Cn%20%20%20%20%20%20%20%20%20%20Results%5Cu00a0%5Cn%20%20%20%20%20%20%20%20%20%20Cortical%20lesions%20were%20detected%20in%2015%20of%2020%20patients%20%2875%25%29.%20MP2RAGE%20revealed%20a%20total%20of%20190%20intracortical%20lesions%20%28median%2C%204%20lesions%5C%2Fcase%20%5Brange%2C%200%5Cu201344%5D%29%20and%20216%20leukocortical%20lesions%20%28median%2C%202%20lesions%5C%2Fcase%20%5Brange%2C%200%5Cu201375%5D%29.%20Although%20the%20number%20of%20white%20matter%20lesions%20correlated%20with%20the%20total%20number%20of%20leukocortical%20lesions%20%28r%20%3D%200.91%2C%20P%20%26lt%3B%200.001%29%2C%20no%20correlation%20was%20observed%20between%20the%20number%20of%20white%20matter%20or%20leukocortical%20lesions%20and%20the%20number%20of%20intracortical%20lesions.%20Furthermore%2C%20the%20number%20of%20leukocortical%20lesions%20but%20not%20intracortical%20or%20white-matter%20lesions%20was%20significantly%20correlated%20with%20cognitive%20impairment%20%28r%20%3D%200.63%2C%20P%20%3D%200.04%2C%20corrected%20for%20multiple%20comparisons%29.%5Cn%20%20%20%20%20%20%20%20%20%20Conclusions%5Cu00a0%5Cn%20%20%20%20%20%20%20%20%20%20This%20study%20highlights%20the%20notable%20prevalence%20of%20cortical%20lesions%20at%20the%20early%20stage%20of%20MS%20identified%20by%207%20T%20MRI.%20There%20may%20be%20a%20potential%20divergence%20in%20the%20underlying%20pathophysiological%20mechanisms%20driving%20distinct%20lesion%20types%2C%20notably%20between%20intracortical%20lesions%20and%20white%20matter%5C%2Fleukocortical%20lesions.%20Moreover%2C%20during%20the%20early%20disease%20phase%2C%20leukocortical%20lesions%20more%20effectively%20accounted%20for%20cognitive%20deficits.%22%2C%22date%22%3A%22November%202024%22%2C%22language%22%3A%22en-US%22%2C%22DOI%22%3A%2210.1097%5C%2FRLI.0000000000001082%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjournals.lww.com%5C%2Finvestigativeradiology%5C%2Fabstract%5C%2F2024%5C%2F11000%5C%2Fcortical_lesions_as_an_early_hallmark_of_multiple.1.aspx%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22UP3H3ICX%22%2C%22B4EWFM7E%22%2C%225P5FWCR9%22%2C%226KPLZTET%22%2C%229L2KHJ5X%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222025-09-12T07%3A59%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22EFR2IKPY%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maarouf%20et%20al.%22%2C%22parsedDate%22%3A%222024-05-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMaarouf%2C%20A.%2C%20Stellmann%2C%20J.P.%2C%20Rico%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Demortiere%2C%20S.%2C%20Durozard%2C%20P.%2C%20Zaaraoui%2C%20W.%2C%20Ranjeva%2C%20J.-P.%2C%20Pelletier%2C%20J.%20and%20Audoin%2C%20B.%20%282024%29%20%26%23x201C%3BActive%20and%20non-active%20progression%20independent%20of%20relapse%20activity%20within%20the%20first%2020%20years%20of%20relapsing%20multiple%20sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Neurology%2C%20Neurosurgery%2C%20and%20Psychiatry%26lt%3B%5C%2Fi%26gt%3B%2C%20p.%20jnnp-2024-333597.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjnnp-2024-333597%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjnnp-2024-333597%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Active%20and%20non-active%20progression%20independent%20of%20relapse%20activity%20within%20the%20first%2020%20years%20of%20relapsing%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%20Patrick%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wafaa%22%2C%22lastName%22%3A%22Zaaraoui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Progression%20independent%20of%20relapse%20activity%20%28PIRA%29%20has%20been%20described%20since%20the%20early%20stage%20of%20relapsing%20multiple%20sclerosis%20%28RMS%29.%20However%2C%20little%20is%20known%20about%20the%20relation%20between%20PIRA%20and%20inflammatory%20activity%20that%20is%20particularly%20important%20at%20this%20stage%20of%20the%20disease.%5CnMETHOD%3A%20We%20included%20110%20patients%20in%20a%20prospective%20study%20within%2018%20months%20of%20RMS%20onset.%20MRI%20examinations%20and%20clinical%20visits%20were%20scheduled%20on%20the%20same%20day%20for%20months%200%2C%206%2C%2012%2C%2024%2C%2036%2C%2060%2C%2084%2C%20120%2C%20180%20and%20240.%5CnRESULTS%3A%20The%20mean%20%28SD%29%20age%20of%20patients%20was%2030%20%286.7%29%20years%20at%20inclusion%20and%20median%20%28range%29%20follow-up%2015%20%289-20%29%20years.%20Analysis%20of%201118%20between-visit%20intervals%20revealed%2093%20confirmed%20disability%20accumulation%20events%20in%2068%20%2862%25%29%20patients%3A%2050%20%2854%25%29%20events%20related%20to%20relapse%20activity%20worsening%20and%2043%20%2846%25%29%20PIRA%20events%2C%20including%2017%20%2818%25%29%20with%20MRI%20activity.%20The%20risk%20of%20PIRA%20between%20two%20visits%20%28stable%20event%20as%20the%20reference%20category%29%20was%20associated%20with%20Expanded%20Disability%20Status%20Scale%20%28EDSS%29%20score%20%28HR%3A%201.41%3B%2095%25%20CI%3A%201.18%20to%201.69%3B%20p%26lt%3B0.001%29%2C%20disease%20duration%20%28HR%3A%200.75%3B%2095%25%5Cu2009CI%3A%200.62%20to%200.90%3B%20p%26lt%3B0.005%29%20and%20new%20lesions%20between%20the%20visits%20%28HR%3A%201.09%20per%20lesion%3B%2095%25%5Cu2009CI%3A%201.01%20to%201.17%3B%20p%26lt%3B0.05%29.%20As%20compared%20with%20PIRA%20events%20with%20MRI%20activity%2C%20PIRA%20events%20without%20such%20activity%20occurred%20in%20patients%20with%20more%20disability%20%28mean%20EDSS%20score%203%2C%20p%26lt%3B0.05%29%2C%20longer%20disease%20duration%20%28mean%2011%20years%2C%20p%26lt%3B0.001%29%20and%20greater%20number%20of%20T2-weighted%20lesions%20%28p%26lt%3B0.05%29.%5CnCONCLUSION%3A%20This%20study%20evidenced%20that%20inflammatory%20activity%20increases%20the%20risk%20of%20PIRA%20in%20early%20RMS%2C%20arguing%20that%20a%20significant%20part%20of%20PIRA%20is%20accessible%20to%20treatment%20targeting%20inflammation%20in%20these%20patients.%22%2C%22date%22%3A%222024-05-06%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fjnnp-2024-333597%22%2C%22ISSN%22%3A%221468-330X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22UP3H3ICX%22%2C%22B4EWFM7E%22%2C%22P66W67T8%22%2C%226KPLZTET%22%2C%229L2KHJ5X%22%5D%2C%22dateModified%22%3A%222025-09-12T07%3A58%3A59Z%22%7D%7D%2C%7B%22key%22%3A%225G3SGMDG%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Graille-Avy%20et%20al.%22%2C%22parsedDate%22%3A%222024-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGraille-Avy%2C%20L.%2C%20Boutiere%2C%20C.%2C%20Rigollet%2C%20C.%2C%20Perriguey%2C%20M.%2C%20Rico%2C%20A.%2C%20Demortiere%2C%20S.%2C%20Durozard%2C%20P.%2C%20Hilezian%2C%20F.%2C%20Vely%2C%20F.%2C%20Bertault-Peres%2C%20P.%2C%20Pelletier%2C%20J.%2C%20Maarouf%2C%20A.%20and%20Audoin%2C%20B.%20%282024%29%20%26%23x201C%3BEffect%20of%20Prior%20Treatment%20With%20Fingolimod%20on%20Early%20and%20Late%20Response%20to%20Rituximab%5C%2FOcrelizumab%20in%20Patients%20With%20Multiple%20Sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2C%2011%283%29%2C%20p.%20e200231.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200231%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200231%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effect%20of%20Prior%20Treatment%20With%20Fingolimod%20on%20Early%20and%20Late%20Response%20to%20Rituximab%5C%2FOcrelizumab%20in%20Patients%20With%20Multiple%20Sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lisa%22%2C%22lastName%22%3A%22Graille-Avy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Rigollet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Perriguey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Vely%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Bertault-Peres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20Real-life%20studies%20noted%20that%20the%20risk%20of%20disease%20activity%20in%20multiple%20sclerosis%20%28MS%29%20after%20switching%20to%20rituximab%20%28RTX%29%20or%20ocrelizumab%20%28OCR%29%20may%20be%20unequal%20depending%20on%20prior%20disease-modifying%20therapy%20%28DMT%29%2C%20with%20a%20higher%20risk%20associated%20with%20fingolimod%20%28FING%29.%5CnMETHODS%3A%20We%20performed%20a%20retrospective%20analysis%20of%20a%20structured%20prospective%20data%20collection%20including%20all%20consecutive%20patients%20with%20relapsing%20MS%20who%20were%20prescribed%20RTX%5C%2FOCR%20in%20the%20MS%20center%20of%20Marseille.%20Cox%20proportional%20hazards%20models%20were%20applied%20to%20clinical%20and%20MRI%20outcomes.%5CnRESULTS%3A%20We%20included%20321%20patients%20with%20a%20median%20%28interquartile%20range%20%5BIQR%5D%29%20follow-up%20of%203.5%20years%20%281.5-5%29%20after%20RTX%5C%2FOCR%20initiation.%20At%20the%20first%20RTX%5C%2FOCR%20infusion%2C%20the%20mean%20%28SD%29%20age%20of%20patients%20was%2037%20%2810%29%20years%2C%20and%20the%20median%20%28IQR%29%20disease%20duration%20was%208%20years%20%283-15%29%3A%2068%20patients%20did%20not%20receive%20treatment%20before%20RTX%5C%2FOCR%20and%20108%20switched%20from%20FING%2C%2047%20from%20low%20efficacy%20therapy%2C%20and%2098%20from%20natalizumab.%20For%20statistical%20analysis%2C%20the%20group%20%26quot%3BFING%26quot%3B%20was%20divided%20into%20%26quot%3Bshort-FING%26quot%3B%20and%20%26quot%3Blong-FING%26quot%3B%20groups%20according%20to%20the%20median%20value%20of%20the%20group%26%23039%3Bs%20washout%20period%20%2827%20days%29.%20On%20Cox%20proportional%20hazards%20analysis%2C%20for%20only%20the%20%26quot%3Blong-FING%26quot%3B%20group%2C%20the%20risk%20of%20relapse%20within%20the%20first%206%20months%20of%20RTX%5C%2FOCR%20was%20increased%20as%20compared%20with%20patients%20without%20previous%20DMT%20%28hazard%20ratio%20%5BHR%5D%3A%208.78%3B%2095%25%20CI%201.72-44.86%3B%20p%20%26lt%3B%200.01%29.%20Previous%20DMT%20and%20washout%20period%20duration%20of%20FING%20had%20no%20effect%20on%20B-cell%20levels%20at%206%20months.%20Beyond%20the%20first%206%20months%20of%20RTX%5C%2FOCR%2C%20age%20%26lt%3B40%20years%20was%20associated%20with%20increased%20risk%20of%20relapse%20%28HR%3A%203.93%3B%2095%25%20CI%201.30-11.89%3B%20p%20%3D%200.01%29%2C%20male%20sex%20with%20increased%20risk%20of%20new%20T2%20lesions%20%28HR%3A%202.26%3B%2095%25%20CI%201.08-4.74%3B%20p%20%3D%200.03%29%2C%20and%20EDSS%20%5Cu22652%20with%20increased%20risk%20of%20disability%20accumulation%20%28HR%3A%203.01%3B%2095%25%20CI%201.34-6.74%3B%20p%20%26lt%3B%200.01%29.%20Previous%20DMT%20had%20no%20effect%20on%20the%20effectiveness%20of%20RTX%5C%2FOCR%20beyond%206%20months%20after%20initiation.%5CnDISCUSSION%3A%20For%20patients%20switching%20from%20FING%20to%20RTX%5C%2FOCR%2C%20the%20risk%20of%20disease%20reactivation%20within%20the%20first%206%20months%20of%20treatment%20was%20increased%20as%20compared%20with%20patients%20with%20other%20DMT%20or%20no%20previous%20DMT%20only%20when%20the%20washout%20period%20exceeded%2026%20days.%20Neither%20FING%20nor%20other%20previous%20DMT%20reduced%20the%20effectiveness%20of%20RTX%5C%2FOCR%20beyond%20the%20first%206%20months%20of%20treatment.%22%2C%22date%22%3A%222024-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000200231%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-09-12T07%3A58%3A52Z%22%7D%7D%2C%7B%22key%22%3A%22NMDESKDG%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Demortiere%20et%20al.%22%2C%22parsedDate%22%3A%222024-04-23%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDemortiere%2C%20S.%2C%20Joubert%2C%20B.%2C%20Benaiteau%2C%20M.%2C%20Hilezian%2C%20F.%2C%20Boutiere%2C%20C.%2C%20Rico%2C%20A.%2C%20Stolowy%2C%20N.%2C%20Dubois%2C%20V.%2C%20Audoin%2C%20B.%2C%20Maarouf%2C%20A.%20and%20Pelletier%2C%20J.%20%282024%29%20%26%23x201C%3BAnti-IgLON5%20Disease%20With%20Inaugural%20Bilateral%20Neuropapillitis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%26lt%3B%5C%2Fi%26gt%3B%2C%20102%288%29%2C%20p.%20e209284.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000209284%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000209284%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Anti-IgLON5%20Disease%20With%20Inaugural%20Bilateral%20Neuropapillitis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Joubert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Benaiteau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natacha%22%2C%22lastName%22%3A%22Stolowy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valerie%22%2C%22lastName%22%3A%22Dubois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222024-04-23%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FWNL.0000000000209284%22%2C%22ISSN%22%3A%221526-632X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-03-29T08%3A57%3A08Z%22%7D%7D%2C%7B%22key%22%3A%22JVQG8Z5Y%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cruz%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-26%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCruz%2C%20E.S.%2C%20Fortanier%2C%20E.%2C%20Hilezian%2C%20F.%2C%20Maarouf%2C%20A.%2C%20Bouti%26%23xE8%3Bre%2C%20C.%2C%20Demorti%26%23xE8%3Bre%2C%20S.%2C%20Rico%2C%20A.%2C%20Delmont%2C%20E.%2C%20Pelletier%2C%20J.%2C%20Attarian%2C%20S.%20and%20Audoin%2C%20B.%20%282024%29%20%26%23x201C%3BFactors%20affecting%20the%20topography%20of%20nitrous%20oxide-induced%20neurological%20complications%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20Journal%20of%20Neurology%26lt%3B%5C%2Fi%26gt%3B%2C%20p.%20e16291.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fene.16291%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fene.16291%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Factors%20affecting%20the%20topography%20of%20nitrous%20oxide-induced%20neurological%20complications%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%20Sole%22%2C%22lastName%22%3A%22Cruz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Fortanier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Bouti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demorti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilien%22%2C%22lastName%22%3A%22Delmont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shahram%22%2C%22lastName%22%3A%22Attarian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20factors%20underlying%20the%20topography%20of%20nitrous%20oxide%20%28N2O%29-induced%20neurological%20complications%20are%20unknown.%5CnMETHODS%3A%20We%20included%20all%20consecutive%20patients%20admitted%20to%20the%20university%20hospital%20of%20Marseille%20for%20N2O-induced%20neurological%20complications%20in%20a%20prospective%20observational%20study.%20Patients%20underwent%20neurological%20examination%2C%20spinal%20cord%20magnetic%20resonance%20imaging%2C%20and%20nerve%20conduction%20studies%20within%20the%20first%204%5Cu2009weeks%20after%20admission.%5CnRESULTS%3A%20In%20total%2C%2061%20patients%20were%20included%3A%2045%25%20with%20myeloneuropathy%2C%2034%25%20with%20isolated%20myelopathy%2C%20and%2021%25%20with%20isolated%20neuropathy.%20On%20multivariable%20analysis%2C%20the%20odds%20of%20myelopathy%20were%20associated%20with%20the%20amount%20of%20weekly%20N2O%20consumption%20%28~600%5Cu2009g%20cylinder%20per%20week%2C%20odds%20ratio%20%5BOR%5D%20%3D%5Cu20091.11%2C%2095%25%20confidence%20interval%20%5BCI%5D%20%3D%5Cu20091.001-1.24%29.%20The%20extent%20of%20the%20myelopathy%20%28number%20of%20vertebral%20segments%29%20was%20correlated%20with%20the%20number%20of%20~600-g%20cylinders%20consumed%20weekly%20%28%5Cu03c1%5Cu2009%3D%5Cu20090.40%2C%20p%5Cu2009%26lt%3B%5Cu20090.005%29.%20The%20odds%20of%20neuropathy%20were%20associated%20with%20the%20duration%20of%20consumption%20%28per%20month%3B%20OR%5Cu2009%3D%5Cu20091.29%2C%2095%25%20CI%5Cu2009%3D%5Cu20091.05-1.58%29.%20Mean%20lower-limb%20motor%20nerve%20amplitude%20was%20correlated%20with%20the%20duration%20of%20consumption%20%28in%20months%3B%20%5Cu03c1%5Cu2009%3D%5Cu2009-0.34%2C%20p%5Cu2009%26lt%3B%5Cu20090.05%29.%5CnCONCLUSIONS%3A%20The%20odds%20of%20myelopathy%20increased%20with%20the%20amount%20of%20N2O%20consumption%2C%20and%20the%20odds%20of%20neuropathy%20increased%20with%20the%20duration%20of%20N2O%20exposure%2C%20which%20suggests%20distinct%20pathophysiological%20mechanisms%20underlying%20these%20two%20neurological%20complications.%22%2C%22date%22%3A%222024-03-26%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fene.16291%22%2C%22ISSN%22%3A%221468-1331%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-09-19T07%3A43%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22LKL8F93N%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Venet%20et%20al.%22%2C%22parsedDate%22%3A%222024-01-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BVenet%2C%20M.%2C%20Lepine%2C%20A.%2C%20Maarouf%2C%20A.%2C%20Biotti%2C%20D.%2C%20Boutiere%2C%20C.%2C%20Casez%2C%20O.%2C%20Cohen%2C%20M.%2C%20Durozard%2C%20P.%2C%20Demorti%26%23xE8%3Bre%2C%20S.%2C%20Giorgi%2C%20L.%2C%20Maillart%2C%20E.%2C%20Mathey%2C%20G.%2C%20Mazzola%2C%20L.%2C%20Rico%2C%20A.%2C%20Camdessanche%2C%20J.-P.%2C%20Deiva%2C%20K.%2C%20Pelletier%2C%20J.%20and%20Audoin%2C%20B.%20%282024%29%20%26%23x201C%3BControl%20of%20disease%20activity%20with%20large%20extended-interval%20dosing%20of%20rituximab%5C%2Focrelizumab%20in%20highly%20active%20pediatric%20multiple%20sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BMultiple%20Sclerosis%20%28Houndmills%2C%20Basingstoke%2C%20England%29%26lt%3B%5C%2Fi%26gt%3B%2C%20p.%2013524585231223069.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585231223069%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585231223069%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Control%20of%20disease%20activity%20with%20large%20extended-interval%20dosing%20of%20rituximab%5C%2Focrelizumab%20in%20highly%20active%20pediatric%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melany%22%2C%22lastName%22%3A%22Venet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Lepine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Biotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demorti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Giorgi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Mazzola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kumaran%22%2C%22lastName%22%3A%22Deiva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22Recent%20studies%20in%20adults%20suggested%20that%20extended-interval%20dosing%20of%20rituximab%5C%2Focrelizumab%20%28RTX%5C%2FOCR%29%20larger%20than%2012%20months%20was%20safe%20and%20could%20improve%20safety.%20This%20was%20an%20observational%20cohort%20study%20of%20very%20active%20pediatric-onset%20multiple%20sclerosis%20%28PoMS%29%20%28median%20%28range%29%20age%2C%2016%20%2812-17%29%20years%29%20treated%20with%20RTX%5C%2FOCR%20with%206%20month%20standard-interval%20dosing%20%28n%20%3D%209%29%20or%20early%20extended-interval%20dosing%20%28n%20%3D%2012%2C%20median%20%28range%29%20interval%2018%20months%20%2812-25%29%29.%20Within%20a%20median%20%28range%29%20follow-up%20of%2031%20%2812-63%29%20months%20after%20RTX%5C%2FOCR%20onset%2C%20one%20patient%20%28standard-interval%29%20experienced%20relapse%20and%20no%20patient%20showed%20disability%20worsening%20or%20new%20T2-weighted%20lesions.%20This%20study%20suggests%20that%20the%20effectiveness%20of%20RTX%5C%2FOCR%20is%20maintained%20with%20a%20median%20extended-interval%20dosing%20of%2018%20months%20in%20patients%20with%20very%20active%20PoMS.%22%2C%22date%22%3A%222024-01-02%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1177%5C%2F13524585231223069%22%2C%22ISSN%22%3A%221477-0970%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-09-12T07%3A59%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22CBEZGFUB%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Claverie%20et%20al.%22%2C%22parsedDate%22%3A%222023-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BClaverie%2C%20R.%2C%20Perriguey%2C%20M.%2C%20Rico%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Demortiere%2C%20S.%2C%20Durozard%2C%20P.%2C%20Hilezian%2C%20F.%2C%20Dubrou%2C%20C.%2C%20Vely%2C%20F.%2C%20Pelletier%2C%20J.%2C%20Audoin%2C%20B.%20and%20Maarouf%2C%20A.%20%282023%29%20%26%23x201C%3BEfficacy%20of%20Rituximab%20Outlasts%20B-Cell%20Repopulation%20in%20Multiple%20Sclerosis%3A%20Time%20to%20Rethink%20Dosing%3F%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2C%2010%285%29%2C%20p.%20e200152.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200152%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200152%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Efficacy%20of%20Rituximab%20Outlasts%20B-Cell%20Repopulation%20in%20Multiple%20Sclerosis%3A%20Time%20to%20Rethink%20Dosing%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roxane%22%2C%22lastName%22%3A%22Claverie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Perriguey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clea%22%2C%22lastName%22%3A%22Dubrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Vely%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20Patients%20with%20multiple%20sclerosis%20%28PwMS%29%20receiving%20extended%20dosing%20of%20rituximab%20%28RTX%29%20have%20exhibited%20no%20return%20of%20disease%20activity%2C%20which%20suggests%20that%20maintenance%20of%20deep%20depletion%20of%20circulating%20B%20cells%20is%20not%20necessary%20to%20maintain%20the%20efficacy%20of%20RTX%20in%20MS.%5CnMETHODS%3A%20This%20was%20a%20prospective%20monocentric%20observational%20study%20including%20all%20consecutive%20PwMS%20who%20started%20or%20continued%20RTX%20after%202019%2C%20when%20the%20medical%20staff%20decided%20to%20extend%20the%20dosing%20interval%20up%20to%2024%20months%20for%20all%20patients.%20Circulating%20B-cell%20subsets%20were%20monitored%20regularly%20and%20systematically%20in%20case%20of%20relapse.%20The%20first%20extended%20interval%20was%20analyzed.%5CnRESULTS%3A%20We%20included%20236%20PwMS%20%2881%25%20with%20relapsing-remitting%20MS%3B%20mean%20%5BSD%5D%20age%2043%20%5B12%5D%20years%3B%20median%20%5Brange%5D%20EDSS%20score%204%20%5B0-8%5D%3B%20mean%20relapse%20rate%20during%20the%20year%20before%20RTX%20start%201.09%20%5B0.99%5D%3B%2041.5%25%20with%20MRI%20activity%29.%20The%20median%20number%20of%20RTX%20infusions%20before%20extension%20was%204%20%281-13%29.%20At%20the%20time%20of%20the%20analysis%2C%20the%20median%20delay%20in%20dosing%20was%2017%20months%20%288-39%29%3B%20the%20median%20proportion%20of%20circulating%20CD19%2B%20B%20cells%20was%207%25%20%280-25%29%20of%20total%20lymphocytes%20and%20that%20of%20CD27%2B%20memory%20B%20cells%20was%204%25%20%280-16%29%20of%20total%20B%20cells.%20The%20mean%20annual%20relapse%20rate%20did%20not%20differ%20before%20and%20after%20the%20extension%3A%200.03%20%280.5%29%20and%200.04%20%280.15%29%20%28p%20%3D%200.51%29.%20Similarly%2C%20annual%20relapse%20rates%20did%20not%20differ%20before%20and%20after%20extension%20in%20patients%20with%20EDSS%20score%20%5Cu22643%20%28n%20%3D%2079%29%20or%20disease%20duration%20%5Cu22645%20years%20%28n%20%3D%2071%29%20at%20RTX%20onset.%20During%20the%20%26quot%3Bextended%20dosing%26quot%3B%20period%2C%20MRI%20demonstrated%20no%20lesion%20accrual%20in%20228%20of%20the%20236%20patients%20%2897%25%29.%20Five%20patients%20experienced%20clinical%20relapse%2C%20which%20was%20confirmed%20by%20MRI.%20In%20these%20patients%2C%20the%20level%20of%20B-cell%20subset%20reconstitution%20at%20the%20time%20of%20the%20relapse%20did%20not%20differ%20from%20that%20for%20patients%20with%20the%20same%20extension%20window.%5CnDISCUSSION%3A%20The%20efficacy%20of%20RTX%20outlasted%20substantial%20reconstitution%20of%20circulating%20B%20cells%20in%20PwMS%2C%20which%20suggests%20that%20renewal%20of%20the%20immune%20system%20underlies%20the%20prolonged%20effect%20of%20RTX%20in%20MS.%20These%20findings%20suggest%20that%20extended%20interval%20dosing%20of%20RTX%20that%20leads%20to%20a%20significant%20reconstitution%20of%20circulating%20B%20cells%20is%20safe%20in%20PwMS%2C%20could%20reduce%20the%20risk%20of%20infection%2C%20and%20could%20improve%20vaccine%20efficacy.%22%2C%22date%22%3A%222023-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000200152%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-08-29T07%3A43%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22RTM5VRM7%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Demortiere%20et%20al.%22%2C%22parsedDate%22%3A%222023-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDemortiere%2C%20S.%2C%20Maarouf%2C%20A.%2C%20Rico%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Hilezian%2C%20F.%2C%20Durozard%2C%20P.%2C%20Pelletier%2C%20J.%20and%20Audoin%2C%20B.%20%282023%29%20%26%23x201C%3BDisease%20Evolution%20in%20Women%20With%20Highly%20Active%20MS%20Who%20Suspended%20Natalizumab%20During%20Pregnancy%20vs%20Rituximab%5C%2FOcrelizumab%20Before%20Conception%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2C%2010%285%29%2C%20p.%20e200161.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200161%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200161%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Disease%20Evolution%20in%20Women%20With%20Highly%20Active%20MS%20Who%20Suspended%20Natalizumab%20During%20Pregnancy%20vs%20Rituximab%5C%2FOcrelizumab%20Before%20Conception%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20In%20women%20with%20highly%20active%20multiple%20sclerosis%20%28MS%29%2C%20suspending%20rituximab%20%28RTX%29%20for%20planning%20pregnancy%20is%20associated%20with%20low%20disease%20reactivation.%20Whether%20this%20strategy%20reduces%20the%20risk%20of%20disease%20reactivity%20as%20compared%20with%20suspending%20natalizumab%20%28NTZ%29%203%20months%20after%20conception%20is%20unclear.%5CnMETHODS%3A%20We%20retrospectively%20included%20women%20with%20MS%20followed%20in%20our%20department%20during%20pregnancy%20and%201%20year%20after%20birth%20who%20suspended%20NTZ%20at%20the%20end%20of%20the%20first%20trimester%20%28option%20mostly%20proposed%20before%202016%29%20or%20suspended%20RTX%5C%2Focrelizumab%20%28RTX%5C%2FOCR%29%20in%20the%20year%20before%20conception%20%28option%20proposed%20since%202016%29.%5CnRESULTS%3A%20In%20women%20who%20suspended%20NTZ%2C%2045%20pregnancies%20resulted%20in%203%20miscarriages%20and%2042%20live%20births%2C%20including%201%20newborn%20with%20major%20malformations.%20In%20women%20who%20suspended%20RTX%5C%2FOCR%2C%2037%20pregnancies%20resulted%20in%203%20miscarriages%20and%2033%20live%20births%3B%201%20pregnancy%20was%20terminated%20for%20malformation.%20During%20pregnancy%2C%20relapse%20occurred%20in%203%5C%2F42%20%287.1%25%29%20patients%20of%20the%20NTZ%20group%20and%201%5C%2F33%20%283%25%29%20of%20the%20RTX%5C%2FOCR%20group%20%28p%20%3D%200.6%29.%20After%20delivery%2C%20relapse%20occurred%20in%209%5C%2F42%20%2821.4%25%29%20patients%20of%20the%20NTZ%20group%20and%200%5C%2F33%20of%20the%20RTX%5C%2FOCR%20group%20%28p%20%26lt%3B%200.01%29.%20In%20the%20NTZ%20group%2C%208%5C%2F9%20relapses%20occurred%20in%20patients%20who%20restarted%20NTZ%20less%20than%204%20weeks%20after%20delivery.%20The%20proportion%20of%20patients%20with%20gadolinium-enhanced%20and%5C%2For%20new%20T2%20lesions%20on%20brain%20or%20spinal%20cord%20MRI%20performed%20after%20delivery%20was%20higher%20in%20the%20NTZ%20than%20RTX%5C%2FOCR%20group%20%2814%5C%2F40%20%5B35%25%5D%20vs%201%5C%2F31%20%5B3%25%5D%20patients%2C%20p%20%3D%200.001%29%2C%20the%20proportion%20with%20EDSS%20score%20progression%20during%20the%20period%20including%20pregnancy%20and%20the%20year%20after%20delivery%20was%20higher%20%287%5C%2F42%20%5B17%25%5D%20vs%200%5C%2F33%20patients%2C%20p%20%3D%200.01%29%2C%20and%20the%20proportion%20fulfilling%20NEDA-3%20during%20this%20period%20was%20lower%20%2821%5C%2F40%20%5B53%25%5D%20vs%2030%5C%2F31%20%5B97%25%5D%20patients%2C%20p%20%26lt%3B%200.001%29.%5CnDISCUSSION%3A%20Suspending%20RTX%5C%2FOCR%20in%20the%20year%20before%20conception%20in%20women%20with%20highly%20active%20MS%20was%20associated%20with%20no%20disease%20reactivation%20during%20and%20after%20pregnancy.%20As%20previously%20reported%2C%20stopping%20NTZ%20at%20the%20end%20of%20the%20first%20trimester%20was%20associated%20with%20disease%20reactivation.%20In%20women%20receiving%20NTZ%20who%20are%20planning%20pregnancy%2C%20a%20bridge%20to%20RTX%5C%2FOCR%20for%20pregnancy%20or%20continuing%20NTZ%20until%20week%2034%20are%20both%20reasonable%20clinical%20decisions.%20The%20RTX%5C%2FOCR%20option%20is%20more%20comfortable%20for%20women%20and%20reduces%20the%20exposure%20of%20infants%20to%20monoclonal%20antibodies.%22%2C%22date%22%3A%222023-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000200161%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-08-29T07%3A43%3A01Z%22%7D%7D%2C%7B%22key%22%3A%226GQS6B3H%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maarouf%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMaarouf%2C%20A.%2C%20Audoin%2C%20B.%2C%20Gherib%2C%20S.%2C%20El%20Mendili%2C%20M.M.%2C%20Viout%2C%20P.%2C%20Pariollaud%2C%20F.%2C%20Bouti%26%23xE8%3Bre%2C%20C.%2C%20Rico%2C%20A.%2C%20Guye%2C%20M.%2C%20Ranjeva%2C%20J.-P.%2C%20Zaaraoui%2C%20W.%20and%20Pelletier%2C%20J.%20%282022%29%20%26%23x201C%3BGrey-matter%20sodium%20concentration%20as%20an%20individual%20marker%20of%20multiple%20sclerosis%20severity%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BMultiple%20Sclerosis%20Journal%26lt%3B%5C%2Fi%26gt%3B%2C%2028%2812%29%2C%20pp.%201903%26%23x2013%3B1912.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585221102587%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585221102587%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Grey-matter%20sodium%20concentration%20as%20an%20individual%20marker%20of%20multiple%20sclerosis%20severity%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soraya%22%2C%22lastName%22%3A%22Gherib%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohamed%20Mounir%22%2C%22lastName%22%3A%22El%20Mendili%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Viout%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanelly%22%2C%22lastName%22%3A%22Pariollaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Bouti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wafaa%22%2C%22lastName%22%3A%22Zaaraoui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%5D%2C%22abstractNote%22%3A%22Objective%3AQuantification%20of%20brain%20injury%20in%20patients%20with%20variable%20disability%20despite%20similar%20disease%20duration%20may%20be%20relevant%20to%20identify%20the%20mechanisms%20underlying%20disability%20in%20multiple%20sclerosis%20%28MS%29.%20We%20aimed%20to%20compare%20grey-matter%20sodium%20abnormalities%20%28GMSAs%29%2C%20a%20parameter%20reflecting%20neuronal%20and%20astrocyte%20dysfunction%2C%20in%20MS%20patients%20with%20benign%20multiple%20sclerosis%20%28BMS%29%20and%20non-benign%20multiple%20sclerosis%20%28NBMS%29.Methods%3AWe%20identified%20never-treated%20BMS%20patients%20in%20our%20local%20MS%20database%20of%201352%20patients.%20A%20group%20with%20NBMS%20was%20identified%20with%20same%20disease%20duration.%20All%20participants%20underwent%2023Na%20magnetic%20resonance%20imaging%20%28MRI%29.%20The%20existence%20of%20GMSA%20was%20detected%20by%20statistical%20analysis.Results%3AIn%20total%2C%20102%20individuals%20were%20included%20%2821%20BMS%2C%2025%20NBMS%20and%2056%20controls%29.%20GMSA%20was%20detected%20in%2010%20BMS%20and%2019%20NBMS%20%2811%5C%2F16%20relapsing-remitting%20multiple%20sclerosis%20%28RRMS%29%20and%208%5C%2F9%20secondary%20progressive%20multiple%20sclerosis%20%28SPMS%29%20patients%29%20%28p%3F%3D%3F0.05%29.%20On%20logistic%20regression%20including%20the%20presence%20or%20absence%20of%20GMSA%2C%20thalamic%20volume%2C%20cortical%20grey-matter%20volume%20and%20T2-weighted%20lesion%20load%2C%20thalamic%20volume%20was%20independently%20associated%20with%20BMS%20status%20%28odds%20ratio%20%28OR%29%3F%3D%3F0.64%20for%20each%20unit%29.%20Nonetheless%2C%20the%20absence%20of%20GMSA%20was%20independently%20associated%20when%20excluding%20patients%20with%20significant%20cognitive%20alteration%20%28n%3F%3D%3F7%29%20from%20the%20BMS%20group%20%28OR%3F%3D%3F4.6%29.Conclusion%3ADetection%20of%20GMSA%20in%20individuals%20and%20thalamic%20volume%20are%20promising%20to%20differentiate%20BMS%20from%20NBMS%20as%20compared%20with%20cortical%20or%20whole%20grey-matter%20atrophy%20and%20T2-weighted%20lesions.%22%2C%22date%22%3A%222022-10-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1177%5C%2F13524585221102587%22%2C%22ISSN%22%3A%221352-4585%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585221102587%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22QU2QXBVV%22%2C%22UP3H3ICX%22%2C%22B4EWFM7E%22%2C%22P66W67T8%22%2C%226KPLZTET%22%2C%22F2AGIUQU%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22JMKK2PYJ%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Poullet%20et%20al.%22%2C%22parsedDate%22%3A%222022-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPoullet%2C%20Z.%2C%20Pique%2C%20J.%2C%20Maarouf%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Rico%2C%20A.%2C%20Demortiere%2C%20S.%2C%20Durozard%2C%20P.%2C%20Papeix%2C%20C.%2C%20Maillart%2C%20E.%2C%20Collongues%2C%20N.%2C%20Ayrignac%2C%20X.%2C%20Zephir%2C%20H.%2C%20Deschamps%2C%20R.%2C%20Ciron%2C%20J.%2C%20Pelletier%2C%20J.%2C%20Marignier%2C%20R.%20and%20Audoin%2C%20B.%20%282022%29%20%26%23x201C%3BPure%20Relapsing%20Short%20Myelitis%3A%20Part%20of%20the%20Multiple%20Sclerosis%20Spectrum%20or%20New%20Entity%3F%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2C%209%284%29%2C%20p.%20e1167.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000001167%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000001167%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pure%20Relapsing%20Short%20Myelitis%3A%20Part%20of%20the%20Multiple%20Sclerosis%20Spectrum%20or%20New%20Entity%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z%5Cu00e9lia%22%2C%22lastName%22%3A%22Poullet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Pique%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Collongues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Ayrignac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Deschamps%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20Pure%20relapsing%20short%20myelitis%20with%20clinical%20and%20paraclinical%20features%20suggesting%20multiple%20sclerosis%20%28MS%29%20has%20been%20described%20recently.%20Here%2C%20we%20evaluated%20the%20existence%20of%20this%20potential%20new%20form%20of%20MS%20by%20retrospectively%20searching%20for%20similar%20cases%20in%20the%20databases%20of%20the%20French%20tertiary%20MS%20centers.%5CnMETHODS%3A%20Patients%20were%20included%20based%20on%20the%20present%20criteria%3A%20at%20least%202%20short%20%28%26lt%3B3%20vertebral%20segments%29%20myelitis%20episodes%3B%20minimum%20follow-up%20of%203%20years%3B%20no%20MS-like%20brain%20lesion%20during%20all%20the%20follow-up%3B%20tested%20negative%20for%20both%20anti-myelin%20oligodendrocyte%20glycoprotein%20and%20anti-aquaporin%204%20antibodies%20in%20serum%3B%20presence%20of%20oligoclonal%20bands%20in%20CSF%3B%20and%20comprehensive%20workup%20to%20exclude%20alternative%20diagnoses.%5CnRESULTS%3A%20Eighteen%20patients%20fulfilled%20all%20criteria.%20The%20sex%20ratio%20%28females%5C%2Fmales%29%20was%205%5C%2F1%3B%20the%20median%20%28range%29%20age%20at%20first%20relapse%20was%2035.5%20%2825-54%29%20years%2C%20the%20disease%20duration%20was%2080.5%20%2850-308%29%20months%2C%20and%20the%20annualized%20relapse%20rate%20was%200.36%20%280.1-0.5%29.%20The%20median%20%28range%29%20number%20of%20relapses%20per%20patient%20was%202%20%282-5%29%2C%20and%20the%20median%20%28range%29%20Expanded%20Disability%20Status%20Scale%20score%20at%20last%20follow-up%20was%201%20%280-7.5%29.%20In%20CSF%2C%20the%20median%20%28range%29%20protein%20level%20was%200.34%20g%5C%2FL%20%280.18-0.77%29%2C%20and%20the%20median%20%28range%29%20number%20of%20mononuclear%20cells%20was%203%20%280-28%29.%20Spinal%20cord%20MRI%20demonstrated%20a%20median%20%28range%29%20number%20of%202%20%281-5%29%20lesions%20per%20examination%20and%203%20%5B1-7%5D%20on%20the%20last%20examination.%20Fifty-five%20percent%20of%20lesions%20involved%20the%20cervical%20levels.%20Secondary%20progressive%20evolution%20occurred%20in%203%20of%2018%20%2817%25%29%20patients.%5CnDISCUSSION%3A%20Pure%20spinal%20MS%20could%20be%20a%20rare%20entity%20in%20the%20MS%20disease%20spectrum.%20However%2C%20the%20existence%20of%20a%20distinct%20entity%20in%20the%20inflammatory%20CNS%20disorders%20cannot%20be%20excluded.%22%2C%22date%22%3A%222022-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000001167%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%2C%22NLCL528K%22%5D%2C%22dateModified%22%3A%222025-04-16T14%3A27%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22JZB2NE65%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Perriguey%20et%20al.%22%2C%22parsedDate%22%3A%222022-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPerriguey%2C%20M.%2C%20Maarouf%2C%20A.%2C%20Stellmann%2C%20J.-P.%2C%20Rico%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Demortiere%2C%20S.%2C%20Durozard%2C%20P.%2C%20Pelletier%2C%20J.%20and%20Audoin%2C%20B.%20%282022%29%20%26%23x201C%3BHypogammaglobulinemia%20and%20Infections%20in%20Patients%20With%20Multiple%20Sclerosis%20Treated%20With%20Rituximab%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2C%209%281%29%2C%20p.%20e1115.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000001115%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000001115%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Hypogammaglobulinemia%20and%20Infections%20in%20Patients%20With%20Multiple%20Sclerosis%20Treated%20With%20Rituximab%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Perriguey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Patrick%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20To%20determine%20the%20frequency%20of%20hypogammaglobulinemia%20and%20infections%20in%20patients%20with%20multiple%20sclerosis%20%28PwMS%29%20receiving%20rituximab%20%28RTX%29.%5CnMETHODS%3A%20This%20prospective%20observational%20study%20included%20all%20consecutive%20PwMS%20receiving%20RTX%20at%20the%20university%20hospital%20of%20Marseille%2C%20France%2C%20between%202015%20and%202020.%20Patient%20visits%20occurred%20at%20least%20every%206%20months.%5CnRESULTS%3A%20We%20included%20188%20patients%20%28151%20with%20relapsing-remitting%20MS%3B%20the%20mean%20age%20was%2043.4%20years%20%5BSD%2012.9%5D%2C%20median%20disease%20duration%2010%20years%20%5Brange%200-36%5D%2C%20median%20Expanded%20Disability%20Status%20Scale%205%20%5Brange%200-8%5D%2C%20median%20follow-up%203.5%20years%20%5Brange%201-5.8%5D%2C%20and%20median%20number%20of%20RTX%20infusions%205%20%5Brange%201-9%5D%29.%20Overall%2C%20317%20symptomatic%20infections%20and%2013%20severe%20infections%20occurred%20in%20133%20of%20188%20%2870.7%25%29%20and%2011%20of%20188%20%285.9%25%29%20patients%2C%20respectively.%20After%204%20years%2C%2024.4%25%20of%20patients%20%2895%25%20CI%2018.0-33.1%29%20were%20free%20of%20any%20infection%20and%2092.0%25%20%2895%25%20CI%2087.1-97.1%29%20had%20not%20experienced%20a%20severe%20infection.%20At%20RTX%20onset%2C%20the%20immunoglobulin%20G%20%28IgG%29%20level%20was%20abnormal%20in%2032%20of%20188%20%2817%25%29%20patients.%20After%20RTX%2C%20IgG%20level%20was%20%26lt%3B7%2C%20%26lt%3B6%2C%20%26lt%3B4%20and%20%26lt%3B2%20g%5C%2FL%20for%2083%20%2844%25%29%2C%2044%20%2823.4%25%29%2C%208%20%284.2%25%29%20and%201%20%280.53%25%29%20patients%2C%20respectively.%20The%20risk%20of%20infection%20was%20associated%20with%20reduced%20IgG%20levels%20%28multivariate%20Cox%20proportional%20hazards%20hazard%20ratio%20%5BHR%5D%20%3D%200.86%2C%2095%25%20CI%200.75-0.98%2C%20p%20%3D%200.03%29.%20The%20risk%20of%20reduced%20IgG%20level%20%26lt%3B6%20g%5C%2FL%20increased%20with%20age%20%28HR%20%3D%201.36%2C%2095%25%20CI%201.05-1.75%2C%20p%20%3D%200.01%29.%5CnDISCUSSION%3A%20In%20PwMS%20receiving%20RTX%2C%20reduced%20IgG%20level%20was%20frequent%20and%20interacted%20with%20the%20risk%20of%20infection.%22%2C%22date%22%3A%222022-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000001115%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%2C%229L2KHJ5X%22%2C%22NLCL528K%22%5D%2C%22dateModified%22%3A%222025-05-28T08%3A33%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22GAIYH54I%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rico%20et%20al.%22%2C%22parsedDate%22%3A%222021-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BRico%2C%20A.%2C%20Ninove%2C%20L.%2C%20Maarouf%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Durozard%2C%20P.%2C%20Demortiere%2C%20S.%2C%20Saba%20Villarroel%2C%20P.M.%2C%20Amroun%2C%20A.%2C%20Fouri%26%23xE9%3B%2C%20T.%2C%20de%20Lamballerie%2C%20X.%2C%20Pelletier%2C%20J.%20and%20Audoin%2C%20B.%20%282021%29%20%26%23x201C%3BDetermining%20the%20best%20window%20for%20BNT162b2%20mRNA%20vaccination%20for%20SARS-CoV-2%20in%20patients%20with%20multiple%20sclerosis%20receiving%20anti-CD20%20therapy%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BMultiple%20Sclerosis%20Journal%20-%20Experimental%2C%20Translational%20and%20Clinical%26lt%3B%5C%2Fi%26gt%3B%2C%207%284%29%2C%20p.%2020552173211062142.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F20552173211062142%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F20552173211062142%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Determining%20the%20best%20window%20for%20BNT162b2%20mRNA%20vaccination%20for%20SARS-CoV-2%20in%20patients%20with%20multiple%20sclerosis%20receiving%20anti-CD20%20therapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Ninove%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paola%20Mariela%22%2C%22lastName%22%3A%22Saba%20Villarroel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdennour%22%2C%22lastName%22%3A%22Amroun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Toscane%22%2C%22lastName%22%3A%22Fouri%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22de%20Lamballerie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22We%20studied%20the%20serologic%20response%20to%20the%20BNT162b2%20mRNA%20vaccine%20at%20four%20weeks%20after%20the%20second%20dose%20in%20patients%20with%20RRMS%20treated%20with%20rituximab%20with%20extended-interval%20dosing%20%28n%5Cu2009%3D%5Cu200926%29.%20At%20four%20weeks%2C%2073%25%20of%20patients%20were%20seropositive.%20No%20patient%20without%20B%20cells%20at%20the%20first%20dose%20%28n%5Cu2009%3D%5Cu20094%29%20was%20seropositive.%20Four%20of%20seven%20%2857%25%29%20patients%20with%20B-cell%20proportion%20%26gt%3B0%25%20and%20%5Cu22645%25%20were%20seropositive.%20All%20patients%20with%20B-cell%20proportion%20%26gt%3B5%25%20%28n%5Cu2009%3D%5Cu200915%29%20were%20seropositive.%20In%20all%20patients%2C%20quantitative%20ELISA%20measures%20after%20vaccination%20were%20correlated%20with%20B-cell%20counts%20measured%20before%20vaccination.%20In%20patients%20receiving%20rituximab%2C%20seropositivity%20after%20BNT162b2%20mRNA%20vaccination%20emerged%20only%20after%20B-cell%20repopulation.%22%2C%22date%22%3A%222021-10%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1177%5C%2F20552173211062142%22%2C%22ISSN%22%3A%222055-2173%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222022-12-03T05%3A53%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22DXZ6FCYF%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hilezian%20et%20al.%22%2C%22parsedDate%22%3A%222021-08-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BHilezian%2C%20F.%2C%20Maarouf%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Rico%2C%20A.%2C%20Demortiere%2C%20S.%2C%20Kerschen%2C%20P.%2C%20Sene%2C%20T.%2C%20Bensa-Koscher%2C%20C.%2C%20Giannesini%2C%20C.%2C%20Capron%2C%20J.%2C%20Mekinian%2C%20A.%2C%20Camdessanch%26%23xE9%3B%2C%20J.-P.%2C%20Androdias%2C%20G.%2C%20Marignier%2C%20R.%2C%20Collongues%2C%20N.%2C%20Casez%2C%20O.%2C%20Coclitu%2C%20C.%2C%20Vaillant%2C%20M.%2C%20Mathey%2C%20G.%2C%20Ciron%2C%20J.%2C%20Pelletier%2C%20J.%20and%20Audoin%2C%20B.%20%282021%29%20%26%23x201C%3BTNF-%26%23x3B1%3B%20inhibitors%20used%20as%20steroid-sparing%20maintenance%20monotherapy%20in%20parenchymal%20CNS%20sarcoidosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Neurology%2C%20Neurosurgery%20%26amp%3B%20Psychiatry%26lt%3B%5C%2Fi%26gt%3B%2C%2092%288%29%2C%20pp.%20890%26%23x2013%3B896.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjnnp-2020-325665%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjnnp-2020-325665%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22TNF-%5Cu03b1%20inhibitors%20used%20as%20steroid-sparing%20maintenance%20monotherapy%20in%20parenchymal%20CNS%20sarcoidosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Kerschen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Sene%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Bensa-Koscher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Giannesini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Capron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arsene%22%2C%22lastName%22%3A%22Mekinian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00e9raldine%22%2C%22lastName%22%3A%22Androdias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Collongues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catalina%22%2C%22lastName%22%3A%22Coclitu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Vaillant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22Objective%20To%20assess%20the%20efficacy%20of%20tumour%20necrosis%20factor-%5Cu03b1%20%28TNF-%5Cu03b1%29%20inhibitors%20used%20as%20steroid-sparing%20monotherapy%20in%20central%20nervous%20system%20%28CNS%29%20parenchymal%20sarcoidosis.%5CnMethods%20The%20French%20Multiple%20Sclerosis%20and%20Neuroinflammation%20Centers%20retrospectively%20identified%20patients%20with%20definite%20or%20probable%20CNS%20sarcoidosis%20treated%20with%20TNF-%5Cu03b1%20inhibitors%20as%20steroid-sparing%20monotherapy.%20Only%20patients%20with%20CNS%20parenchymal%20involvement%20demonstrated%20by%20MRI%20and%20imaging%20follow-up%20were%20included.%20The%20primary%20outcome%20was%20the%20minimum%20dose%20of%20steroids%20reached%20that%20was%20not%20associated%20with%20clinical%20or%20imaging%20worsening%20during%20a%20minimum%20of%203%20months%20after%20dosing%20change.%5CnResults%20Of%20the%20identified%2038%20patients%20with%20CNS%20sarcoidosis%20treated%20with%20TNF-%5Cu03b1%20inhibitors%2C%2023%20fulfilled%20all%20criteria%20%2813%20females%29.%20Treatments%20were%20infliximab%20%28n%3D22%29%20or%20adalimumab%20%28n%3D1%29%20for%20a%20median%20%28IQR%29%20of%2024%20%2817%5Cu201340%29%20months.%20At%20treatment%20initiation%2C%20the%20mean%20%28SD%29%20age%20was%2041.5%20%2810.5%29%20years%20and%20median%20%28IQR%29%20disease%20duration%2022%20%2814%5Cu201349.5%29%20months.%20Overall%2C%2060%25%20of%20patients%20received%20other%20immunosuppressive%20agents%20before%20a%20TNF-%5Cu03b1%20inhibitor.%20The%20mean%20%28SD%29%20minimum%20dose%20of%20steroids%20was%2031.5%20%2833%29%20mg%20before%20TNF-%5Cu03b1%20inhibitor%20initiation%20and%206.5%20%285.5%29%20mg%20after%20%28p%3D0.001%29.%20In%20all%2C%2065%25%20of%20patients%20achieved%20steroids%20dosing%20%26lt%3B6%20mg%5C%2Fday%3B%2061%25%20showed%20clinical%20improvement%2C%2030%25%20stability%20and%209%25%20disease%20worsening.%20Imaging%20revealed%20improvement%20in%2074%25%20of%20patients%20and%20stability%20in%2026%25.%5CnConclusion%20TNF-%5Cu03b1%20inhibitors%20can%20greatly%20reduce%20steroids%20dosing%20in%20patients%20with%20CNS%20parenchymal%20sarcoidosis%2C%20even%20refractory.%5CnClassification%20of%20evidence%20This%20study%20provides%20Class%20IV%20evidence%20that%20TNF-%5Cu03b1%20inhibitor%20used%20as%20steroid-sparing%20monotherapy%20is%20effective%20for%20patients%20with%20CNS%20parenchymal%20sarcoidosis.%22%2C%22date%22%3A%222021%5C%2F08%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1136%5C%2Fjnnp-2020-325665%22%2C%22ISSN%22%3A%220022-3050%2C%201468-330X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjnnp.bmj.com%5C%2Fcontent%5C%2F92%5C%2F8%5C%2F890%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-08-29T07%3A43%3A03Z%22%7D%7D%2C%7B%22key%22%3A%229VNZ397A%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Perez%20et%20al.%22%2C%22parsedDate%22%3A%222021-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPerez%2C%20T.%2C%20Rico%2C%20A.%2C%20Bouti%26%23xE8%3Bre%2C%20C.%2C%20Maarouf%2C%20A.%2C%20Roudot%2C%20M.%2C%20Honor%26%23xE9%3B%2C%20S.%2C%20Pelletier%2C%20J.%2C%20Bertault-Peres%2C%20P.%20and%20Audoin%2C%20B.%20%282021%29%20%26%23x201C%3BComparison%20of%20rituximab%20originator%20%28MabThera%26%23xAE%3B%29%20to%20biosimilar%20%28Truxima%26%23xAE%3B%29%20in%20patients%20with%20multiple%20sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BMultiple%20Sclerosis%20%28Houndmills%2C%20Basingstoke%2C%20England%29%26lt%3B%5C%2Fi%26gt%3B%2C%2027%284%29%2C%20pp.%20585%26%23x2013%3B592.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1352458520912170%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1352458520912170%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Comparison%20of%20rituximab%20originator%20%28MabThera%5Cu00ae%29%20to%20biosimilar%20%28Truxima%5Cu00ae%29%20in%20patients%20with%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Perez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Bouti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marjorie%22%2C%22lastName%22%3A%22Roudot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Honor%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Bertault-Peres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Rituximab%26%23039%3Bs%20originator%20MabThera%5Cu00ae%20or%20Rituxan%5Cu00ae%20has%20demonstrated%20high%20efficacy%20in%20multiple%20sclerosis%20%28MS%29.%20Because%20of%20the%20patent%20expiration%2C%20rituximab%20biosimilars%20have%20been%20developed.%20However%2C%20because%20a%20biosimilar%20is%20not%20the%20exact%20copy%20of%20the%20originator%2C%20the%20efficacy%20and%20safety%20of%20a%20biosimilar%20may%20significantly%20differ.%5CnOBJECTIVES%3A%20To%20compare%20the%20efficacy%20and%20safety%20of%20the%20biosimilar%20Truxima%5Cu00ae%20and%20the%20originator%20MabThera%5Cu00ae%20in%20MS.%5CnMETHODS%3A%20Consecutive%20MS%20patients%20receiving%20MabThera%5Cu00ae%20or%20Truxima%5Cu00ae%20were%20prospectively%20followed%20during%201%5Cu2009year%20after%20treatment%20introduction.%20Allocation%20to%20each%20treatment%20depended%20on%20the%20period%20of%20introduction%20and%20not%20the%20physician%26%23039%3Bs%20choice.%20Lymphocyte%20count%2C%20clinical%20and%20magnetic%20resonance%20imaging%20%28MRI%29%20activity%2C%20Expanded%20Disability%20Status%20Scale%20%28EDSS%29%2C%20and%20adverse%20events%20were%20compared.%5CnRESULTS%3A%20In%20total%2C%20105%20and%2040%20patients%20received%20MabThera%5Cu00ae%20and%20Truxima%5Cu00ae%2C%20respectively.%20The%20two%20groups%20did%20not%20differ%20in%20baseline%20characteristics.%20Effect%20on%20CD19%2B%20lymphocytes%20and%20disease%20activity%20were%20similar%20during%20follow-up.%20EDSS%20remained%20stable%2C%20with%20no%20difference%20between%20groups.%20Adverse%20events%20were%20similar%20between%20groups.%5CnCONCLUSION%3A%20The%20efficacy%20and%20safety%20of%20the%20rituximab%20biosimilar%20Truxima%5Cu00ae%20seem%20equivalent%20to%20the%20originator%20MabThera%5Cu00ae%20in%20MS%20patients.%20Truxima%5Cu00ae%20could%20represent%20a%20relatively%20cheap%20and%20safe%20therapeutic%20alternative%20to%20MabThera%5Cu00ae%20and%20could%20improve%20access%20to%20highly%20efficient%20therapy%20for%20MS%20in%20low-%20or%20middle-income%20countries.%22%2C%22date%22%3A%222021-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1177%5C%2F1352458520912170%22%2C%22ISSN%22%3A%221477-0970%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%5D%2C%22dateModified%22%3A%222025-03-28T08%3A42%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22CQAWPIVJ%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A1497928%2C%22username%22%3A%22fkober%22%2C%22name%22%3A%22Frank%20Kober%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Ffkober%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Demortiere%20et%20al.%22%2C%22parsedDate%22%3A%222020-03-23%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDemortiere%2C%20S.%2C%20Rico%2C%20A.%2C%20Maarouf%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Pelletier%2C%20J.%20and%20Audoin%2C%20B.%20%282020%29%20%26%23x201C%3BMaintenance%20of%20natalizumab%20during%20the%20first%20trimester%20of%20pregnancy%20in%20active%20multiple%20sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BMultiple%20Sclerosis%20%28Houndmills%2C%20Basingstoke%2C%20England%29%26lt%3B%5C%2Fi%26gt%3B%2C%20p.%201352458520912637.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1352458520912637%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1352458520912637%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Maintenance%20of%20natalizumab%20during%20the%20first%20trimester%20of%20pregnancy%20in%20active%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Planning%20pregnancy%20in%20patients%20with%20active%20multiple%20sclerosis%20%28MS%29%20is%20highly%20challenging%20because%20treatment%20withdrawn%20may%20be%20associated%20with%20dramatic%20disease%20reactivation.%5CnOBJECTIVE%3A%20To%20compare%20two%20strategies%20for%20women%20with%20active%20MS%20who%20were%20planning%20pregnancy%3A%20stopping%20natalizumab%20%281%29%20at%20the%20end%20of%20the%20first%20trimester%20and%20%282%29%20at%20conception.%5CnMETHODS%3A%20Standardized%20strategy%20for%20women%20with%20active%20MS%20was%20initiated%20in%20our%20department.%20Maintenance%20of%20natalizumab%20until%20the%20end%20of%20first%20trimester%20was%20recommended%20%28%26quot%3Bsecured%20first%20trimester%26quot%3B%20%28SFT%29%29.%20When%20patients%20refused%2C%20they%20were%20advised%20to%20continue%20until%20conception%20%28%26quot%3Bsecured%20conception%26quot%3B%20%28SC%29%29.%20Predictors%20of%20disease%20activity%20during%20pregnancy%20were%20assessed.%5CnRESULTS%3A%20Forty-six%20pregnancies%20were%20prospectively%20followed%20%2830%20with%20SFT%20and%2016%20with%20SC%29.%20One%20congenital%20anomaly%20occurred%20in%20the%20SC%20group.%20The%20proportions%20of%20patients%20with%20relapse%20and%20disability%20progression%20during%20pregnancy%20were%20lower%20in%20the%20SFT%20than%20in%20the%20SC%20group%20%283.6%25%20vs%2038.5%25%2C%20p%5Cu2009%26lt%3B%5Cu20090.005%20and%203.6%25%20vs%2030.8%25%2C%20p%5Cu2009%26lt%3B%5Cu20090.05%2C%20respectively%29.%20Predictors%20of%20relapse%20and%20disability%20progression%20during%20pregnancy%20were%20the%20time%20when%20natalizumab%20was%20stopped%20%28conception%20vs%20end%20of%20first%20trimester%29%20and%20the%20number%20of%20relapses%20during%20the%20year%20before%20natalizumab.%5CnCONCLUSION%3A%20Maintaining%20natalizumab%20during%20the%20first%20trimester%20may%20reduce%20the%20risk%20of%20disease%20reactivation%20during%20pregnancy%20in%20patients%20with%20active%20MS.%22%2C%22date%22%3A%22Mar%2023%2C%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1177%5C%2F1352458520912637%22%2C%22ISSN%22%3A%221477-0970%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%5D%2C%22dateModified%22%3A%222025-03-11T08%3A54%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22ZGLSTPHS%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Durozard%20et%20al.%22%2C%22parsedDate%22%3A%222020-02%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDurozard%2C%20P.%2C%20Rico%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Maarouf%2C%20A.%2C%20Lacroix%2C%20R.%2C%20Cointe%2C%20S.%2C%20Fritz%2C%20S.%2C%20Brunet%2C%20C.%2C%20Pelletier%2C%20J.%2C%20Marignier%2C%20R.%20and%20Audoin%2C%20B.%20%282020%29%20%26%23x201C%3BComparison%20of%20the%20Response%20to%20Rituximab%20between%20Myelin%20Oligodendrocyte%20Glycoprotein%20and%20Aquaporin-4%20Antibody%20Diseases%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BAnnals%20of%20Neurology%26lt%3B%5C%2Fi%26gt%3B%2C%2087%282%29%2C%20pp.%20256%26%23x2013%3B266.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fana.25648%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fana.25648%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Comparison%20of%20the%20Response%20to%20Rituximab%20between%20Myelin%20Oligodendrocyte%20Glycoprotein%20and%20Aquaporin-4%20Antibody%20Diseases%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romaric%22%2C%22lastName%22%3A%22Lacroix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Cointe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shirley%22%2C%22lastName%22%3A%22Fritz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Brunet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20compare%20response%20to%20rituximab%20%28RTX%29%20between%20adult%20patients%20positive%20for%20myelin%20oligodendrocyte%20glycoprotein%20%28MOG%29%20and%20aquaporin-4%20%28AQP4%29%20antibodies.%5CnMETHODS%3A%20We%20prospectively%20studied%20adult%20patients%20with%20MOG%20or%20AQP4%20antibodies%20who%20received%20RTX%20under%20an%20individualized%20dosing%20schedule%20adapted%20to%20the%20biological%20effect%20of%20RTX%20monitored%20by%20memory%20B-cell%20measurement.%20Memory%20B%20cells%20were%20counted%20monthly%20and%20when%20relapse%20occurred.%20The%20biological%20effect%20of%20RTX%20was%20considered%20significant%20with%20%26lt%3B0.05%25%20memory%20B%20cells%20in%20peripheral%20blood%20lymphocytes.%5CnRESULTS%3A%20In%2016%20patients%20with%20MOG%20antibodies%20and%2029%20with%20AQP4%20antibodies%2C%20mean%20follow-up%20was%2019%20%28range%5Cu2009%3D%5Cu20099-38%29%20and%2038%20%2813-79%29%20months.%20Under%20RTX%2C%2010%20relapses%20occurred%20in%206%20of%2016%20%2837.5%25%29%20patients%20with%20MOG%20antibodies%2C%20and%2013%20occurred%20in%207%20of%2029%20%2824%25%29%20with%20AQP4%20antibodies.%20The%20median%20time%20of%20relapse%20after%20the%20most%20recent%20infusion%20was%202.6%20%280.6-5.8%29%20and%207%20%280.8-13%29%20months%2C%20respectively%20%28p%20%26lt%3B%5Cu20090.001%29.%20Memory%20B%20cells%20had%20reemerged%20in%202%20of%2010%20%2820%25%29%20relapses%20in%20patients%20with%20MOG%20antibodies%20and%2012%20of%2013%20%2892.5%25%29%20with%20AQP4%20antibodies%20%28p%20%26lt%3B%5Cu20090.001%29.%5CnINTERPRETATION%3A%20In%20AQP4%20antibody-associated%20disorder%2C%20relapse%20mostly%20occurs%20when%20the%20biological%20effect%20of%20RTX%20decreases%2C%20which%20argues%20for%20treatment%20efficacy.%20In%20MOG%20antibody-associated%20disorder%2C%20the%20efficacy%20of%20RTX%20is%20not%20constant%2C%20because%20one-third%20of%20patients%20showed%20relapse%20despite%20an%20effective%20biological%20effect%20of%20RTX.%20In%20this%20subpopulation%2C%20memory%20B-cell%20depletion%20was%20unable%20to%20prevent%20relapse%2C%20which%20was%20probably%20caused%20by%20different%20immunological%20mechanisms.%20These%20findings%20should%20be%20used%20to%20improve%20treatment%20strategies%20for%20MOG%20antibody-associated%20disorder.%20ANN%20NEUROL%202020%3B87%3A256-266.%22%2C%22date%22%3A%22Feb%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fana.25648%22%2C%22ISSN%22%3A%221531-8249%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-03-28T08%3A42%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22CTB8FBXW%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maarouf%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMaarouf%2C%20A.%2C%20Rico%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Perriguey%2C%20M.%2C%20Demortiere%2C%20S.%2C%20Pelletier%2C%20J.%2C%20Audoin%2C%20B.%20and%20Under%20the%20aegis%20of%20OFSEP%20%282020%29%20%26%23x201C%3BExtending%20rituximab%20dosing%20intervals%20in%20patients%20with%20MS%20during%20the%20COVID-19%20pandemic%20and%20beyond%3F%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%20-%20Neuroimmunology%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2C%207%285%29%2C%20p.%20e825.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000000825%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000000825%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Extending%20rituximab%20dosing%20intervals%20in%20patients%20with%20MS%20during%20the%20COVID-19%20pandemic%20and%20beyond%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Perriguey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Under%20the%20aegis%20of%20OFSEP%22%7D%5D%2C%22abstractNote%22%3A%22Objective%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20To%20evaluate%20disease%20activity%20in%20patients%20with%20relapsing-remitting%20MS%20%28RRMS%29%20receiving%20rituximab%20with%20an%20extended%20dosing%20interval.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20the%20context%20of%20COVID-19%20pandemic%2C%20this%20was%20an%20interim%20analysis%20of%20an%20ongoing%20prospective%20observational%20study%20of%20patients%20who%20were%20stable%20on%20rituximab%20for%20at%20least%206%20months%20and%20who%20had%20a%20planned%20extended%20dosing%20interval%20of%2024%20months.%20Only%20data%20for%20patients%20with%20active%20RRMS%20before%20rituximab%20were%20analyzed.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Among%20177%20patients%20receiving%20rituximab%2C%2033%20had%20RRMS%20and%20MRI%20activity%20before%20rituximab%20and%20at%20least%208%20months%20of%20follow-up%20after%20the%20last%20infusion.%20The%20mean%20%28SD%29%20age%20was%2040%20%2814%29%20years%2C%2025%20were%20females%2C%20the%20mean%20disease%20duration%20was%2010%20%286.8%29%20years%2C%20the%20mean%20annual%20relapse%20rate%20%28ARR%29%20before%20rituximab%20was%201.7%20%281.3%29%2C%20and%20the%20median%20Expanded%20Disability%20Status%20Scale%20%28EDSS%29%20score%20before%20rituximab%20was%204.5%20%281%5Cu20137%29.%20Before%20extended%20dosing%2C%20when%20rituximab%20was%20infused%20every%206%20months%2C%20the%20mean%20%28SD%29%20ARR%20decreased%20to%200.04%20%280.1%29%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20p%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%26lt%3B%200.0001%29%20and%20the%20EDSS%20score%20to%204%20%280%5Cu20137%29%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20p%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D%200.04%29.%20At%20the%20time%20of%20this%20analysis%2C%20the%20median%20follow-up%20since%20the%20last%20infusion%20was%2011%20%288%5Cu201331%29%20months.%20No%20patient%20showed%20relapse%20or%20disability%20progression.%20In%20total%2C%2030%20patients%20had%20at%20least%201%20MRI%20performed%20since%20the%20last%20infusion%20%28median%20time%20between%20the%20last%20MRI%20and%20the%20last%20infusion%2010%20%5B8%5Cu201331%5D%20months%29.%20No%20MRI%20showed%20activity.%20The%20CD19%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2B%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20cell%20proportion%20was%20%26gt%3B1%25%20for%2010%20of%2025%20patients%20at%20the%20last%20count%20%28median%20time%208%20%5B6%5Cu201325%5D%20months%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20An%20extended%20dosing%20interval%20for%20rituximab%20for%20patients%20with%20stable%20MS%20during%20the%20COVID-19%20pandemic%20may%20be%20associated%20with%20a%20low%20risk%20of%20disease%20activity.%22%2C%22date%22%3A%2209%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000000825%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fnn.neurology.org%5C%2Flookup%5C%2Fdoi%5C%2F10.1212%5C%2FNXI.0000000000000825%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-03-28T08%3A42%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22VYKTFGXN%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Touati%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BTouati%2C%20J.%2C%20Rico%2C%20G.%2C%20Habert%2C%20P.%2C%20G%26%23xE9%3Brault%2C%20M.%2C%20Gaubert%2C%20J.Y.%2C%20Chagnaud%2C%20C.%20and%20Varoquaux%2C%20A.%20%282020%29%20%26%23x201C%3BPrevention%20of%20nosocomial%20transmission%20of%20SARS-CoV-2%20using%20pre-operative%20chest%20CT%3A%20a%20monocentric%20study%20during%20the%20outbreak%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BThe%20Journal%20of%20Hospital%20Infection%26lt%3B%5C%2Fi%26gt%3B%2C%20106%281%29%2C%20pp.%20186%26%23x2013%3B188.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jhin.2020.07.005%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jhin.2020.07.005%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prevention%20of%20nosocomial%20transmission%20of%20SARS-CoV-2%20using%20pre-operative%20chest%20CT%3A%20a%20monocentric%20study%20during%20the%20outbreak%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Touati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Habert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22G%5Cu00e9rault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Y.%22%2C%22lastName%22%3A%22Gaubert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Chagnaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Varoquaux%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2209%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jhin.2020.07.005%22%2C%22ISSN%22%3A%221532-2939%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22TXRC8BWU%22%2C%22KBIRKXGV%22%5D%2C%22dateModified%22%3A%222025-03-19T13%3A32%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22YJY3TF5Y%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Melenotte%20et%20al.%22%2C%22parsedDate%22%3A%222019-10-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMelenotte%2C%20C.%2C%20Loukil%2C%20A.%2C%20Rico%2C%20A.%2C%20Lepidi%2C%20H.%20and%20Raoult%2C%20D.%20%282019%29%20%26%23x201C%3BBlood%20Culture%26%23x2013%3BNegative%20Cardiovascular%20Infection%20in%20a%20Patient%20With%20Multiple%20Sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BOpen%20Forum%20Infectious%20Diseases%26lt%3B%5C%2Fi%26gt%3B%2C%206%2810%29%2C%20p.%20ofz429.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofz429%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofz429%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Blood%20Culture%5Cu2013Negative%20Cardiovascular%20Infection%20in%20a%20Patient%20With%20Multiple%20Sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9a%22%2C%22lastName%22%3A%22Melenotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmed%22%2C%22lastName%22%3A%22Loukil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hubert%22%2C%22lastName%22%3A%22Lepidi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Raoult%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20A%20patient%20with%20multiple%20sclerosis%20presented%20with%20seronegative%20C.%20burnetii%20endocarditis%20diagnosed%20using%20C.%20burnetii%5Cu2013specific%20polymerase%20chain%20reaction%20and%20fluorescence%20in%20situ%20hybridization%20on%20cardiovascular%20biopsy.%20This%20case%20supports%20the%20necessity%20of%20a%20systematic%20polymerase%20chain%20reaction%20testing%20of%20removed%20cardiac%20valves%20because%20blood%20culture%5Cu2013negative%20endocarditis%20can%20be%20pauci-symptomatic%2C%20and%20serological%20tests%20can%20be%20negative%20in%20cases%20of%20immunosuppression.%22%2C%22date%22%3A%222019-10-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Fofid%5C%2Fofz429%22%2C%22ISSN%22%3A%222328-8957%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fofid%5C%2Farticle%5C%2Fdoi%5C%2F10.1093%5C%2Fofid%5C%2Fofz429%5C%2F5580761%22%2C%22collections%22%3A%5B%22NLCL528K%22%5D%2C%22dateModified%22%3A%222024-12-03T08%3A55%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22Y2SCP87G%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22De%20Looze%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDe%20Looze%2C%20C.%2C%20Moreau%2C%20N.%2C%20Reni%26%23xE9%3B%2C%20L.%2C%20Kelly%2C%20F.%2C%20Ghio%2C%20A.%2C%20Rico%2C%20A.%2C%20Audoin%2C%20B.%2C%20Viallet%2C%20F.%2C%20Pelletier%2C%20J.%20and%20Petrone%2C%20C.%20%282019%29%20%26%23x201C%3BEffects%20of%20cognitive%20impairment%20on%20prosodic%20parameters%20of%20speech%20production%20planning%20in%20multiple%20sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Neuropsychology%26lt%3B%5C%2Fi%26gt%3B%2C%2013%281%29%2C%20pp.%2022%26%23x2013%3B45.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fjnp.12127%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fjnp.12127%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effects%20of%20cognitive%20impairment%20on%20prosodic%20parameters%20of%20speech%20production%20planning%20in%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22De%20Looze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22No%5Cu00e9mie%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Reni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Finnian%22%2C%22lastName%22%3A%22Kelly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Ghio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Viallet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caterina%22%2C%22lastName%22%3A%22Petrone%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2203%5C%2F2019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1111%5C%2Fjnp.12127%22%2C%22ISSN%22%3A%2217486645%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2F10.1111%5C%2Fjnp.12127%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A53Z%22%7D%7D%2C%7B%22key%22%3A%2296FZI46K%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maarouf%20et%20al.%22%2C%22parsedDate%22%3A%222018-06%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMaarouf%2C%20A.%2C%20Bouti%26%23xE8%3Bre%2C%20C.%2C%20Rico%2C%20A.%2C%20Audoin%2C%20B.%20and%20Pelletier%2C%20J.%20%282018%29%20%26%23x201C%3BHow%20much%20progress%20has%20there%20been%20in%20the%20second-line%20treatment%20of%20multiple%20sclerosis%3A%20A%202017%20update%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BRevue%20Neurologique%26lt%3B%5C%2Fi%26gt%3B%2C%20174%286%29%2C%20pp.%20429%26%23x2013%3B440.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.neurol.2018.01.369%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.neurol.2018.01.369%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22How%20much%20progress%20has%20there%20been%20in%20the%20second-line%20treatment%20of%20multiple%20sclerosis%3A%20A%202017%20update%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Bouti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Pelletier%22%7D%5D%2C%22abstractNote%22%3A%22In%201993%2C%20the%20US%20Food%20and%20Drug%20Administration%20%28FDA%29%20approved%20the%20first%20drug%20specifically%20for%20treating%20multiple%20sclerosis%20%28MS%29.%20More%20than%20two%20decades%20later%2C%20a%20dozen%20such%20treatments%20are%20now%20available.%20Of%20these%2C%20four%20are%20considered%20second-line%20treatments%20for%20use%20in%20escalation%20strategies%20and%20two%20new%20drugs%20are%20currently%20undergoing%20accreditation%20procedures.%20Soon%2C%20they%20will%20provide%20clinicians%20with%20a%20range%20of%20six%20effective%20disease-modifying%20treatments%20%28DMTs%29%20to%20thwart%20the%20inflammatory%20processes%20in%20MS%20patients%20with%20active%20disease.%20However%2C%20while%20such%20a%20large%20number%20of%20DMTs%20for%20MS%20can%20help%20to%20control%20early%20inflammation%2C%20any%20decisions%20to%20be%20made%20by%20clinicians%20have%20also%20been%20made%20substantially%20more%20complex.%20This%20complexity%20is%20increased%20by%20the%20lack%20of%20head-to-head%20studies%20comparing%20these%20second-line%20therapies%20and%20the%20benefit-risk%20profiles%20for%20each%20of%20these%20drugs%2C%20which%20are%20likely%20to%20vary%20among%20patients.%20Ultimately%2C%20good%20awareness%20of%20the%20benefits%20and%2C%20more%20important%2C%20the%20risks%20of%20each%20MS%20DMT%20is%20crucial%20for%20the%20effective%20management%20of%20inflammation%20in%20MS.%22%2C%22date%22%3A%22Jun%202018%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.neurol.2018.01.369%22%2C%22ISSN%22%3A%220035-3787%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22TASKKSHJ%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Meunier%20et%20al.%22%2C%22parsedDate%22%3A%222018%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMeunier%2C%20B.%2C%20Rico%2C%20A.%2C%20Seguier%2C%20J.%2C%20Boutiere%2C%20C.%2C%20Ebbo%2C%20M.%2C%20Harle%2C%20J.R.%2C%20Schleinitz%2C%20N.%20and%20Pelletier%2C%20J.%20%282018%29%20%26%23x201C%3BLife-threatening%20autoimmune%20warm%20hemolytic%20anemia%20following%20treatment%20for%20multiple%20sclerosis%20with%20alemtuzumab%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BMultiple%20Sclerosis%20Journal%26lt%3B%5C%2Fi%26gt%3B%2C%2024%286%29%2C%20pp.%20811%26%23x2013%3B813.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1352458517729766%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1352458517729766%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Life-threatening%20autoimmune%20warm%20hemolytic%20anemia%20following%20treatment%20for%20multiple%20sclerosis%20with%20alemtuzumab%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Meunier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Seguier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Ebbo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Robert%22%2C%22lastName%22%3A%22Harle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Schleinitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Alemtuzumab%20is%20a%20humanized%20monoclonal%20antibody%20directed%20at%20CD52%20approved%20as%20a%20disease-modifying%20therapy%20for%20relapsing%20forms%20of%20multiple%20sclerosis%20%28MS%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Objective%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20To%20describe%20a%20case%20of%20a%20life-threatening%20autoimmune%20anemia%20occurring%20after%20a%20first%20course%20of%20alemtuzumab%20for%20relapsing-remitting%20MS%20in%20a%2028-year-old%20male.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Case%20report.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20A%2028-year-old%20male%20developed%20a%20life-threatening%20autoimmune%20anemia%20occurring%2011%5Cu2009months%20after%20first%20alemtuzumab%20course.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20report%20the%20third%20case%20of%20autoimmune%20hemolytic%20anemia%20following%20treatment%20with%20alemtuzumab%20in%20a%20young%20MS%20patient.%20Due%20to%20the%20severity%20of%20this%20adverse%20event%2C%20neurologists%20using%20this%20treatment%20should%20be%20alert.%22%2C%22date%22%3A%2205%5C%2F2018%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1177%5C%2F1352458517729766%22%2C%22ISSN%22%3A%221352-4585%2C%201477-0970%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fjournals.sagepub.com%5C%2Fdoi%5C%2F10.1177%5C%2F1352458517729766%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A02%3A02Z%22%7D%7D%2C%7B%22key%22%3A%229NIU9JEV%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Doche%20et%20al.%22%2C%22parsedDate%22%3A%222017-03%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDoche%2C%20E.%2C%20Lecocq%2C%20A.%2C%20Maarouf%2C%20A.%2C%20Duhamel%2C%20G.%2C%20Soulier%2C%20E.%2C%20Confort-Gouny%2C%20S.%2C%20Rico%2C%20A.%2C%20Guye%2C%20M.%2C%20Audoin%2C%20B.%2C%20Pelletier%2C%20J.%2C%20Ranjeva%2C%20J.-P.%20and%20Zaaraoui%2C%20W.%20%282017%29%20%26%23x201C%3BHypoperfusion%20of%20the%20thalamus%20is%20associated%20with%20disability%20in%20relapsing%20remitting%20multiple%20sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Neuroradiology.%20Journal%20De%20Neuroradiologie%26lt%3B%5C%2Fi%26gt%3B%2C%2044%282%29%2C%20pp.%20158%26%23x2013%3B164.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.neurad.2016.10.001%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.neurad.2016.10.001%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Hypoperfusion%20of%20the%20thalamus%20is%20associated%20with%20disability%20in%20relapsing%20remitting%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Doche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ang%5Cu00e8le%22%2C%22lastName%22%3A%22Lecocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Duhamel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Soulier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylviane%22%2C%22lastName%22%3A%22Confort-Gouny%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wafaa%22%2C%22lastName%22%3A%22Zaaraoui%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20While%20gray%20matter%20%28GM%29%20perfusion%20abnormalities%20have%20been%20evidenced%20in%20multiple%20sclerosis%20%28MS%29%20patients%2C%20the%20relationships%20with%20disability%20still%20remain%20unclear.%20Considering%20that%20atrophy%20is%20known%20to%20impact%20on%20perfusion%2C%20we%20aimed%20to%20assess%20perfusion%20abnormalities%20in%20GM%20of%20MS%20patients%2C%20outside%20atrophic%20regions%20and%20investigate%20relationships%20with%20disability.%5CnMETHODS%3A%20Brain%20perfusion%20of%2023%20relapsing%20remitting%20MS%20patients%20and%2016%20matched%20healthy%20subjects%20were%20assessed%20at%203T%20using%20the%20pseudo-continuous%20arterial%20spin%20labeling%20magnetic%20resonance%20imaging%20technique.%20In%20order%20to%20locate%20potential%20GM%20perfusion%20abnormalities%20in%20regions%20spared%20by%20atrophy%2C%20we%20combined%20voxelwise%20comparisons%20of%20GM%20cerebral%20blood%20flow%20%28CBF%29%20maps%20%28cortex%20and%20deep%20GM%29%20%28P%26lt%3B0.005%2C%20FWE-corrected%29%20and%20voxel-based-morphometry%20analysis%20%28P%26lt%3B0.005%2C%20FDR-corrected%29%20to%20exclude%20atrophic%20regions.%20Disability%20was%20assessed%20using%20the%20Expanded%20Disability%20Status%20Scale%20%28EDSS%29%20and%20the%20Multiple%20Sclerosis%20Functional%20Composite%20score%20%28MSFC%29.%5CnRESULTS%3A%20In%20patients%2C%20significant%20GM%20hypoperfusion%20outside%20atrophic%20regions%20was%20depicted%20only%20in%20bilateral%20thalami.%20No%20other%20cluster%20was%20found%20to%20be%20hypoperfused%20compared%20to%20controls.%20Perfusion%20of%20thalami%20was%20correlated%20to%20MSFC%20%28P%3D0.011%2C%20rho%3D0.523%29.%20A%20trend%20of%20correlation%20was%20found%20between%20perfusion%20of%20thalami%20and%20EDSS%20%28P%3D0.061%2C%20rho%3D-0.396%29.%5CnCONCLUSION%3A%20In%20relapsing%20remitting%20MS%2C%20perfusion%20abnormalities%20in%20thalamic%20regions%20contribute%20to%20disability.%20These%20findings%20suggest%20that%20functional%20impairments%20of%20thalami%2C%20representing%20a%20major%20brain%20hub%2C%20may%20disturb%20various%20cerebral%20functions%20even%20before%20structural%20damage.%22%2C%22date%22%3A%22Mar%202017%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.neurad.2016.10.001%22%2C%22ISSN%22%3A%220150-9861%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%224U7D3E9U%22%2C%227JR7EDKF%22%2C%22KJQH9V8M%22%2C%22UP3H3ICX%22%2C%22B4EWFM7E%22%2C%22P66W67T8%22%2C%226KPLZTET%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222025-04-16T14%3A27%3A33Z%22%7D%7D%2C%7B%22key%22%3A%227E9BBSTC%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maarouf%20et%20al.%22%2C%22parsedDate%22%3A%222017-01-17%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMaarouf%2C%20A.%2C%20Audoin%2C%20B.%2C%20Pariollaud%2C%20F.%2C%20Gherib%2C%20S.%2C%20Rico%2C%20A.%2C%20Soulier%2C%20E.%2C%20Confort-Gouny%2C%20S.%2C%20Guye%2C%20M.%2C%20Schad%2C%20L.%2C%20Pelletier%2C%20J.%2C%20Ranjeva%2C%20J.-P.%20and%20Zaaraoui%2C%20W.%20%282017%29%20%26%23x201C%3BIncreased%20total%20sodium%20concentration%20in%20gray%20matter%20better%20explains%20cognition%20than%20atrophy%20in%20MS%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%26lt%3B%5C%2Fi%26gt%3B%2C%2088%283%29%2C%20pp.%20289%26%23x2013%3B295.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000003511%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000003511%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Increased%20total%20sodium%20concentration%20in%20gray%20matter%20better%20explains%20cognition%20than%20atrophy%20in%20MS%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanelly%22%2C%22lastName%22%3A%22Pariollaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soraya%22%2C%22lastName%22%3A%22Gherib%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Soulier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylviane%22%2C%22lastName%22%3A%22Confort-Gouny%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lothar%22%2C%22lastName%22%3A%22Schad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wafaa%22%2C%22lastName%22%3A%22Zaaraoui%22%7D%5D%2C%22abstractNote%22%3A%22Objective%3A%20To%20investigate%20whether%20brain%20total%20sodium%20accumulation%20assessed%20by%2023Na%20MRI%20is%20associated%20with%20cognitive%20deficit%20in%20relapsing-remitting%20multiple%20sclerosis%20%28RRMS%29.%5CnMethods%3A%20Eighty-nine%20participants%20were%20enrolled%20in%20the%20study%20%2858%20patients%20with%20RRMS%20with%20a%20disease%20duration%20%5Cu226410%20years%20and%2031%20matched%20healthy%20controls%29.%20Patients%20were%20classified%20as%20cognitively%20impaired%20if%20they%20failed%20at%20least%202%20tasks%20on%20the%20Brief%20Repeatable%20Battery.%20MRI%20was%20performed%20at%203T%20using%2023Na%20MRI%20to%20obtain%20total%20sodium%20concentration%20%28TSC%29%20in%20the%20different%20brain%20compartments%20%28lesions%2C%20normal-appearing%20white%20matter%20%5BNAWM%5D%2C%20gray%20matter%20%5BGM%5D%29%20and%201H-%20magnetization-prepared%20rapid%20gradient%20echo%20to%20assess%20GM%20atrophy%20%28GM%20fraction%29.%5CnResults%3A%20The%20mean%20disease%20duration%20was%203.1%20years%20and%20the%20median%20Expanded%20Disability%20Status%20Scale%20score%20was%201%20%28range%200%5Cu20134.5%29.%20Thirty-seven%20patients%20were%20classified%20as%20cognitively%20preserved%20and%2021%20as%20cognitively%20impaired.%20TSC%20was%20increased%20in%20GM%20and%20NAWM%20in%20cognitively%20impaired%20patients%20compared%20to%20cognitively%20preserved%20patients%20and%20healthy%20controls.%20Voxel-wise%20analysis%20demonstrated%20that%20sodium%20accumulation%20was%20mainly%20located%20in%20the%20neocortex%20in%20cognitively%20impaired%20patients.%20Regression%20analysis%20evidenced%20than%20the%202%20best%20independent%20predictors%20of%20cognitive%20impairment%20were%20GM%20TSC%20and%20age.%20Receiver%20operating%20characteristic%20analyses%20demonstrated%20that%20sensitivity%20and%20specificity%20of%20the%20GM%20TSC%20to%20classify%20patients%20according%20to%20their%20cognitive%20status%20were%2076%25%20and%2071%25%2C%20respectively.%5CnConclusions%3A%20This%20study%20provides%202%20main%20findings.%20%281%29%20In%20RRMS%2C%20total%20sodium%20accumulation%20in%20the%20GM%20is%20better%20associated%20with%20cognitive%20impairment%20than%20GM%20atrophy%3B%20and%20%282%29%20total%20sodium%20accumulation%20in%20patients%20with%20cognitive%20impairment%20is%20mainly%20located%20in%20the%20neocortex.%22%2C%22date%22%3A%2201%5C%2F17%5C%2F2017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1212%5C%2FWNL.0000000000003511%22%2C%22ISSN%22%3A%220028-3878%2C%201526-632X%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.neurology.org%5C%2Fcontent%5C%2F88%5C%2F3%5C%2F289%22%2C%22collections%22%3A%5B%227JR7EDKF%22%2C%22KJQH9V8M%22%2C%22UP3H3ICX%22%2C%22B4EWFM7E%22%2C%22P66W67T8%22%2C%226KPLZTET%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A07Z%22%7D%7D%2C%7B%22key%22%3A%22LM6M7XUS%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Grimaldi-Bensouda%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGrimaldi-Bensouda%2C%20L.%2C%20Rossignol%2C%20M.%2C%20Kon%26%23xE9%3B-Paut%2C%20I.%2C%20Krivitzky%2C%20A.%2C%20Lebrun-Frenay%2C%20C.%2C%20Clet%2C%20J.%2C%20Brassat%2C%20D.%2C%20Papeix%2C%20C.%2C%20Nicolino%2C%20M.%2C%20Benhamou%2C%20P.-Y.%2C%20Fain%2C%20O.%2C%20Costedoat-Chalumeau%2C%20N.%2C%20Courcoux%2C%20M.-F.%2C%20Viallard%2C%20Jean-Fran%26%23xE7%3Bois%2C%20Godeau%2C%20B.%2C%20Papo%2C%20T.%2C%20Vermersch%2C%20P.%2C%20Bourgault-Villada%2C%20I.%2C%20Breart%2C%20G.%2C%20Abenhaim%2C%20L.%2C%20Abbas%2C%20F.%2C%20Abdelmoumni%2C%20A.%2C%20Hilliquin%2C%20P.%2C%20Requeda%2C%20E.%2C%20Adoue%2C%20D.%2C%20Brassat%2C%20D.%2C%20Agard%2C%20C.%2C%20Masseau%2C%20A.%2C%20Aladjidi%2C%20N.%2C%20Clet%2C%20J.%2C%20Fernandes%2C%20H.%2C%20Lemasson%2C%20G.%2C%20Perel%2C%20Y.%2C%20Raymond%2C%20I.%2C%20Richer%2C%20O.%2C%20Vital%2C%20A.%2C%20Allain-Launay%2C%20E.%2C%20Bru%2C%20M.%2C%20Nicolino%2C%20M.%2C%20Thomas%2C%20C.%2C%20Altman%2C%20J.-J.%2C%20Amsallem%2C%20D.%2C%20Aras%2C%20N.%2C%20Boukari%2C%20L.%2C%20Dubrel%2C%20M.%2C%20Fain%2C%20O.%2C%20Letellier%2C%20E.%2C%20Lucidarme%2C%20N.%2C%20Mekinian%2C%20A.%2C%20Morin%2C%20A.-S.%2C%20Stirnemann%2C%20J.%2C%20Atlan%2C%20C.%2C%20Audry%2C%20D.%2C%20Augustin%2C%20J.%2C%20Bakir%2C%20R.%2C%20Bartolucci%2C%20P.%2C%20Chevalier%2C%20X.%2C%20Godeau%2C%20B.%2C%20Guillaud%2C%20C.%2C%20Khellaf%2C%20M.%2C%20Limal%2C%20N.%2C%20Lousteau%2C%20V.%2C%20Mahevas%2C%20M.%2C%20M%26%23xE9%3Bliksetyan%2C%20G.%2C%20Michel%2C%20M.%2C%20Roumier%2C%20M.%2C%20Bayart%2C%20S.%2C%20Bonnet%2C%20F.%2C%20Decaux%2C%20O.%2C%20Bekherraz%2C%20A.%2C%20Brihaye%2C%20B.%2C%20Dachez%2C%20R.%2C%20Daugas%2C%20E.%2C%20Hayem%2C%20G.%2C%20Meyer%2C%20O.%2C%20Papo%2C%20T.%2C%20Pasqualoni%2C%20E.%2C%20Sacre%2C%20K.%2C%20Travert%2C%20F.%2C%20Bellon%2C%20H.%2C%20Beltrand%2C%20J.%2C%20Lefrere%2C%20F.%2C%20Simon%2C%20A.%2C%20Benhamou%2C%20P.-Y.%2C%20Benveniste%2C%20O.%2C%20Bolgert%2C%20F.%2C%20Costedoat-Chalumeau%2C%20N.%2C%20De%20Paz%2C%20R.%2C%20Demeret%2C%20S.%2C%20Fautrel%2C%20B.%2C%20Jacqueminet%2C%20S.%2C%20Louapre%2C%20C.%2C%20Maillart%2C%20E.%2C%20Morel%2C%20N.%2C%20Papeix%2C%20C.%2C%20Rigabert%2C%20J.%2C%20Bensaid%2C%20P.%2C%20Berger%2C%20C.%2C%20Berquin%2C%20P.%2C%20Le%20Moing%2C%20A.-G.%2C%20Berroir%2C%20S.%2C%20Besson%2C%20G.%2C%20Boutte%2C%20C.%2C%20Casez%2C%20O.%2C%20Bonnotte%2C%20B.%2C%20Audia%2C%20S.%2C%20Bossu-Estour%2C%20C.%2C%20Bourgarit%2C%20A.%2C%20Dupuy%2C%20A.%2C%20Keshmandt%2C%20H.%2C%20Bourre%2C%20B.%2C%20Brac%2C%20A.%2C%20Perrin%2C%20A.%2C%20Pondarr%26%23xE9%3B%2C%20C.%2C%20Villar-Fimbel%2C%20S.%2C%20Bruckert%2C%20I.%2C%20Cosson%2C%20A.%2C%20Magy-Bertrand%2C%20N.%2C%20Tisserand%2C%20G.%2C%20Camu%2C%20W.%2C%20Carlander%2C%20B.%2C%20Morales%2C%20R.J.%2C%20Cances%2C%20C.%2C%20Pasquet%2C%20M.%2C%20Castilla%20Lievre%2C%20M.A.%2C%20Chabroux%2C%20S.%2C%20Charif%2C%20M.%2C%20Chatelus%2C%20E.%2C%20Sibilia%2C%20J.%2C%20Chevrant-Breton%2C%20J.%2C%20Clavel%2C%20S.%2C%20Bille-Turc%2C%20F.%2C%20Cohen%2C%20J.%2C%20Courcoux%2C%20M.F.%2C%20Leverger%2C%20G.%2C%20Machet%2C%20L.%2C%20Cuisset%2C%20J.-M.%2C%20Cony-Makhoul%2C%20P.%2C%20Darsy%2C%20P.%2C%20Favre%2C%20S.%2C%20Giraud%2C%20P.%2C%20Leitenschenck%2C%20L.%2C%20Monteiro%2C%20I.%2C%20Morati%2C%20C.%2C%20DeSeze%2C%20J.%2C%20Dinulescu%2C%20M.%2C%20Dhaoui%2C%20T.%2C%20Dommange-Romero%2C%20F.%2C%20Drevard%2C%20E.%2C%20Dupuis%2C%20C.%2C%20Dumuis%2C%20M.-L.%2C%20Durand%2C%20J.-M.%2C%20Farad%2C%20S.%2C%20Lecomte%2C%20P.%2C%20Pierre%2C%20P.%2C%20Fouyssac%2C%20F.%2C%20Gaudin%2C%20P.%2C%20Gautier%2C%20A.%2C%20Gellen-Dautremer%2C%20J.%2C%20Jarrin%2C%20I.%2C%20Richette%2C%20P.%2C%20Georget%2C%20E.%2C%20Gras%2C%20P.%2C%20Moreau%2C%20T.%2C%20Giraud%2C%20E.%2C%20Hacini%2C%20M.%2C%20Mayer%2C%20A.%2C%20Guillaumat%2C%20C.%2C%20Guillaume%2C%20S.%2C%20Guitton%2C%20C.%2C%20Kone-Paut%2C%20I.%2C%20Marsaud%2C%20C.%2C%20Rossi%2C%20L.%2C%20Guyot%2C%20M.-H.%2C%20Hassler%2C%20P.%2C%20Heimfert%2C%20C.%2C%20Heinzlef%2C%20O.%2C%20Hillion%2C%20B.%2C%20Hocquelet%2C%20C.%2C%20Husson%2C%20H.%2C%20Ichai%2C%20P.%2C%20Jeziorski%2C%20E.%2C%20Deslandre%2C%20C.J.%2C%20Le%20Guern%2C%20V.%2C%20Kamenov%2C%20K.%2C%20Kerlan%2C%20V.%2C%20Lemoine%2C%20P.%2C%20Misery%2C%20L.%2C%20Pan-Petesch%2C%20B.%2C%20Krivitzky%2C%20A.%2C%20Labauge%2C%20P.%2C%20Rodier%2C%20M.%2C%20Lacade%2C%20C.%2C%20Razafimahefa%2C%20B.%2C%20Lachgar%2C%20K.%2C%20Larmarau%2C%20M.-P.%2C%20Leblanc%2C%20T.%2C%20Lebrun-Frenay%2C%20C.%2C%20Lef%26%23xE8%3Bbvre%2C%20P.%2C%20Lejoyeux%2C%20P.%2C%20Leske%2C%20C.%2C%20Ly%2C%20K.%2C%20Magy%2C%20L.%2C%20Mansuy%2C%20S.%2C%20Marechaud%2C%20R.%2C%20Martin%20Negrier%2C%20M.-L.%2C%20Sole%2C%20G.%2C%20Maupetit%2C%20J.%2C%20Mazingue%2C%20F.%2C%20Mochon%2C%20S.%2C%20Moktar%2C%20B.%2C%20Morcamp%2C%20D.%2C%20Morlet-Barla%2C%20N.%2C%20Nicolas%2C%20G.%2C%20Pautot%2C%20V.%2C%20Pellier%2C%20I.%2C%20Verret%2C%20J.-L.%2C%20Outteryck%2C%20O.%2C%20Vermersch%2C%20P.%2C%20Pallot-Prades%2C%20B.%2C%20Paquet%2C%20J.M.%2C%20Puechal%2C%20X.%2C%20Sortais%2C%20A.%2C%20Pelletier%2C%20J.%2C%20Rico%2C%20A.%2C%20Pez%2C%20D.%2C%20Stankoff%2C%20B.%2C%20Quittet%2C%20P.%2C%20R%26%23xE9%3Bmy%2C%20C.%2C%20Roba%2C%20E.%2C%20Rosario%2C%20H.%2C%20Roudaut%2C%20N.%2C%20Sonnet%2C%20E.%2C%20Ruel%2C%20M.%2C%20Sebban%2C%20S.%2C%20Schaepelynck%2C%20P.%2C%20Simonin%2C%20M.-J.%2C%20Vial%2C%20C.%2C%20Viallard%2C%20Jean-Francois%2C%20Ladedan%2C%20I.%20and%20Zenone%2C%20T.%20%282017%29%20%26%23x201C%3BRisk%20of%20autoimmune%20diseases%20and%20human%20papilloma%20virus%20%28HPV%29%20vaccines%3A%20Six%20years%20of%20case-referent%20surveillance%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Autoimmunity%26lt%3B%5C%2Fi%26gt%3B%2C%2079%2C%20pp.%2084%26%23x2013%3B90.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jaut.2017.01.005%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jaut.2017.01.005%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Risk%20of%20autoimmune%20diseases%20and%20human%20papilloma%20virus%20%28HPV%29%20vaccines%3A%20Six%20years%20of%20case-referent%20surveillance%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lamiae%22%2C%22lastName%22%3A%22Grimaldi-Bensouda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Rossignol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Kon%5Cu00e9-Paut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Krivitzky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johanna%22%2C%22lastName%22%3A%22Clet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Brassat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Nicolino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Yves%22%2C%22lastName%22%3A%22Benhamou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Fain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Costedoat-Chalumeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-France%22%2C%22lastName%22%3A%22Courcoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Viallard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Godeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Papo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Vermersch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Bourgault-Villada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerard%22%2C%22lastName%22%3A%22Breart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucien%22%2C%22lastName%22%3A%22Abenhaim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Firas%22%2C%22lastName%22%3A%22Abbas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdelhakim%22%2C%22lastName%22%3A%22Abdelmoumni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Hilliquin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Requeda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Adoue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Brassat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Agard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agathe%22%2C%22lastName%22%3A%22Masseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Aladjidi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johanna%22%2C%22lastName%22%3A%22Clet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helder%22%2C%22lastName%22%3A%22Fernandes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwendal%22%2C%22lastName%22%3A%22Lemasson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Perel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Raymond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Richer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Vital%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emma%22%2C%22lastName%22%3A%22Allain-Launay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Bru%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Nicolino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Altman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Amsallem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nazmiye%22%2C%22lastName%22%3A%22Aras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Latifato%22%2C%22lastName%22%3A%22Boukari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Dubrel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Fain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edouard%22%2C%22lastName%22%3A%22Letellier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Lucidarme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ars%5Cu00e8ne%22%2C%22lastName%22%3A%22Mekinian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Sophie%22%2C%22lastName%22%3A%22Morin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Stirnemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Atlan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Audry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Augustin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Redouane%22%2C%22lastName%22%3A%22Bakir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%22%2C%22lastName%22%3A%22Bartolucci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Chevalier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Godeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constance%22%2C%22lastName%22%3A%22Guillaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mehdi%22%2C%22lastName%22%3A%22Khellaf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Limal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valentine%22%2C%22lastName%22%3A%22Lousteau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthieu%22%2C%22lastName%22%3A%22Mahevas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gayane%22%2C%22lastName%22%3A%22M%5Cu00e9liksetyan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Roumier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Bayart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Decaux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amine%22%2C%22lastName%22%3A%22Bekherraz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Brihaye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roger%22%2C%22lastName%22%3A%22Dachez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Daugas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Hayem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Papo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisa%22%2C%22lastName%22%3A%22Pasqualoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karim%22%2C%22lastName%22%3A%22Sacre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Travert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Bellon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Beltrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Lefrere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albane%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Yves%22%2C%22lastName%22%3A%22Benhamou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Benveniste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francis%22%2C%22lastName%22%3A%22Bolgert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Costedoat-Chalumeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raphael%22%2C%22lastName%22%3A%22De%20Paz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Demeret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Fautrel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Jacqueminet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Louapre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Morel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Rigabert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Bensaid%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Berquin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Ga%5Cu00eblle%22%2C%22lastName%22%3A%22Le%20Moing%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Berroir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00e9rard%22%2C%22lastName%22%3A%22Besson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9lia%22%2C%22lastName%22%3A%22Boutte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Bonnotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Audia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Bossu-Estour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Bourgarit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Dupuy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Homa%22%2C%22lastName%22%3A%22Keshmandt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aude%22%2C%22lastName%22%3A%22Brac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Perrin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Pondarr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Villar-Fimbel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Bruckert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Cosson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Magy-Bertrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Tisserand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%22%2C%22lastName%22%3A%22Camu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Carlander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raul%20Juntas%22%2C%22lastName%22%3A%22Morales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude%22%2C%22lastName%22%3A%22Cances%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marlene%22%2C%22lastName%22%3A%22Pasquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Angela%22%2C%22lastName%22%3A%22Castilla%20Lievre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephanie%22%2C%22lastName%22%3A%22Chabroux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mamoud%22%2C%22lastName%22%3A%22Charif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Chatelus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Sibilia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacqueline%22%2C%22lastName%22%3A%22Chevrant-Breton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvaine%22%2C%22lastName%22%3A%22Clavel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Bille-Turc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20France%22%2C%22lastName%22%3A%22Courcoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guy%22%2C%22lastName%22%3A%22Leverger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Machet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Marie%22%2C%22lastName%22%3A%22Cuisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Cony-Makhoul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Darsy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Favre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierrick%22%2C%22lastName%22%3A%22Giraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Leitenschenck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ir%5Cu00e8ne%22%2C%22lastName%22%3A%22Monteiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chafika%22%2C%22lastName%22%3A%22Morati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22DeSeze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monica%22%2C%22lastName%22%3A%22Dinulescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Taher%22%2C%22lastName%22%3A%22Dhaoui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Dommange-Romero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Drevard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mentine%22%2C%22lastName%22%3A%22Dupuis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Laure%22%2C%22lastName%22%3A%22Dumuis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Marc%22%2C%22lastName%22%3A%22Durand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samia%22%2C%22lastName%22%3A%22Farad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Lecomte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peggy%22%2C%22lastName%22%3A%22Pierre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanny%22%2C%22lastName%22%3A%22Fouyssac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Gaudin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Gautier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justine%22%2C%22lastName%22%3A%22Gellen-Dautremer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ir%5Cu00e8ne%22%2C%22lastName%22%3A%22Jarrin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Richette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Georget%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Gras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Giraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maya%22%2C%22lastName%22%3A%22Hacini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Mayer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Guillaumat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9verine%22%2C%22lastName%22%3A%22Guillaume%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Guitton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Kone-Paut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Marsaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Linda%22%2C%22lastName%22%3A%22Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Guyot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Hassler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude%22%2C%22lastName%22%3A%22Heimfert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brigitte%22%2C%22lastName%22%3A%22Hillion%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Hocquelet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Husson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Ichai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Jeziorski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%20Job%22%2C%22lastName%22%3A%22Deslandre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Le%20Guern%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kamen%22%2C%22lastName%22%3A%22Kamenov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Kerlan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Lemoine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Misery%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brigitte%22%2C%22lastName%22%3A%22Pan-Petesch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Krivitzky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Rodier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chadi%22%2C%22lastName%22%3A%22Lacade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Berthe%22%2C%22lastName%22%3A%22Razafimahefa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karim%22%2C%22lastName%22%3A%22Lachgar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Pierre%22%2C%22lastName%22%3A%22Larmarau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Leblanc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Lef%5Cu00e8bvre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Lejoyeux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Leske%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kim%22%2C%22lastName%22%3A%22Ly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Mansuy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Marechaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Laure%22%2C%22lastName%22%3A%22Martin%20Negrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guilhem%22%2C%22lastName%22%3A%22Sole%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Maupetit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Mazingue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Mochon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Blidi%22%2C%22lastName%22%3A%22Moktar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Donald%22%2C%22lastName%22%3A%22Morcamp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Morlet-Barla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Nicolas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vivien%22%2C%22lastName%22%3A%22Pautot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Pellier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Luc%22%2C%22lastName%22%3A%22Verret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Outteryck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Vermersch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatrice%22%2C%22lastName%22%3A%22Pallot-Prades%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Michel%22%2C%22lastName%22%3A%22Paquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Puechal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annie%22%2C%22lastName%22%3A%22Sortais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Pez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Quittet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude%22%2C%22lastName%22%3A%22R%5Cu00e9my%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22El%5Cu00e9na%22%2C%22lastName%22%3A%22Roba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Rosario%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Roudaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Sonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Ruel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Sebban%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Schaepelynck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Jeanne%22%2C%22lastName%22%3A%22Simonin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Vial%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Francois%22%2C%22lastName%22%3A%22Viallard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Ladedan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Zenone%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2205%5C%2F2017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jaut.2017.01.005%22%2C%22ISSN%22%3A%2208968411%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS0896841116302141%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22H8UPCNQI%22%5D%2C%22dateModified%22%3A%222025-05-13T07%3A47%3A26Z%22%7D%7D%2C%7B%22key%22%3A%227SKN6PRI%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maillart%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMaillart%2C%20E.%2C%20Vidal%2C%20J.-S.%2C%20Brassat%2C%20D.%2C%20Stankoff%2C%20B.%2C%20Fromont%2C%20A.%2C%20de%20S%26%23xE8%3Bze%2C%20J.%2C%20Taithe%2C%20F.%2C%20Clavelou%2C%20P.%2C%20Bourre%2C%20B.%2C%20Delvaux%2C%20V.%2C%20Rico%2C%20A.%2C%20Labauge%2C%20P.%2C%20Tourbah%2C%20A.%2C%20Lebrun%2C%20C.%2C%20Pelletier%2C%20J.%2C%20Moreau%2C%20T.%2C%20Louapre%2C%20C.%2C%20Lubetzki%2C%20C.%20and%20Papeix%2C%20C.%20%282017%29%20%26%23x201C%3BNatalizumab-PML%20survivors%20with%20subsequent%20MS%20treatment%3A%20Clinico-radiologic%20outcome%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%20-%20Neuroimmunology%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2C%204%283%29%2C%20p.%20e346.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000000346%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000000346%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Natalizumab-PML%20survivors%20with%20subsequent%20MS%20treatment%3A%20Clinico-radiologic%20outcome%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Sebastien%22%2C%22lastName%22%3A%22Vidal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Brassat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Fromont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22de%20S%5Cu00e8ze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Taithe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Delvaux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ayman%22%2C%22lastName%22%3A%22Tourbah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Louapre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Lubetzki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%5D%2C%22abstractNote%22%3A%22Objective%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20To%20describe%20the%20clinico-radiologic%20outcome%20of%20MS%20patients%20with%20natalizumab-related%20progressive%20multifocal%20leukoencephalopathy%20%28Nz-PML%29%20surviving%20and%20receiving%20disease-modifying%20therapy%20%28DMT%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20describe%20clinical%20and%20radiologic%20evolution%20of%20Nz-PML%20survivors%20in%20an%20observational%20retrospective%20multicenter%20cohort%20to%20clarify%20the%20effect%20of%20different%20subsequent%20MS%20DMT%20strategies.%20Twenty-three%20patients%20from%2011%20centers%20were%20analyzed.%20Outcomes%20were%20%281%29%20clinical%20efficacy%20of%20post-PML%20MS%20DMT%2C%20%282%29%20radiologic%20efficacy%20of%20post-PML%20MS%20DMT%2C%20%283%29%20radiologic%20evolution%20of%20PML%20lesion%2C%20and%20%284%29%20disability%20progression.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20There%20was%20no%20clinical%20worsening%20of%20PML%20symptoms%20with%20a%20stability%20of%20Expanded%20Disability%20Status%20Scale%20at%20the%20last%20follow-up.%20No%20relapse%20was%20reported%20with%20fingolimod%20and%20dimethyl%20fumarate.%20No%20radiologic%20worsening%20of%20Nz-PML%20lesion%20was%20observed%20at%20the%20end%20of%20the%20follow-up.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20this%20large%20cohort%20of%20patients%20with%20Nz-PML%2C%20MS%20therapies%20given%20after%20Nz%20discontinuation%20were%20not%20associated%20with%20PML%20worsening.%20A%20larger%20cohort%20with%20longer%20follow-up%20will%20be%20necessary%20to%20confirm%20this%20therapeutic%20strategy.%22%2C%22date%22%3A%2205%5C%2F2017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000000346%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fnn.neurology.org%5C%2Flookup%5C%2Fdoi%5C%2F10.1212%5C%2FNXI.0000000000000346%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A02%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22L4MQJYF7%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bouti%5Cu00e8re%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBouti%26%23xE8%3Bre%2C%20C.%2C%20Rey%2C%20C.%2C%20Zaaraoui%2C%20W.%2C%20Le%20Troter%2C%20A.%2C%20Rico%2C%20A.%2C%20Crespy%2C%20L.%2C%20Achard%2C%20S.%2C%20Reuter%2C%20F.%2C%20Pariollaud%2C%20F.%2C%20Wirsich%2C%20J.%2C%20Asquinazi%2C%20P.%2C%20Confort-Gouny%2C%20S.%2C%20Soulier%2C%20E.%2C%20Guye%2C%20M.%2C%20Pelletier%2C%20J.%2C%20Ranjeva%2C%20J.-P.%20and%20Audoin%2C%20B.%20%282017%29%20%26%23x201C%3BImprovement%20of%20spasticity%20following%20intermittent%20theta%20burst%20stimulation%20in%20multiple%20sclerosis%20is%20associated%20with%20modulation%20of%20resting-state%20functional%20connectivity%20of%20the%20primary%20motor%20cortices%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BMultiple%20Sclerosis%20%28Houndmills%2C%20Basingstoke%2C%20England%29%26lt%3B%5C%2Fi%26gt%3B%2C%2023%286%29%2C%20pp.%20855%26%23x2013%3B863.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1352458516661640%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1352458516661640%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Improvement%20of%20spasticity%20following%20intermittent%20theta%20burst%20stimulation%20in%20multiple%20sclerosis%20is%20associated%20with%20modulation%20of%20resting-state%20functional%20connectivity%20of%20the%20primary%20motor%20cortices%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Bouti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Rey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wafaa%22%2C%22lastName%22%3A%22Zaaraoui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Le%20Troter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydie%22%2C%22lastName%22%3A%22Crespy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Achard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Reuter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanelly%22%2C%22lastName%22%3A%22Pariollaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Wirsich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Asquinazi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylviane%22%2C%22lastName%22%3A%22Confort-Gouny%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Soulier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Intermittent%20theta%20burst%20stimulation%20%28iTBS%29%20of%20the%20primary%20motor%20cortex%20improves%20transiently%20lower%20limbs%20spasticity%20in%20multiple%20sclerosis%20%28MS%29.%20However%2C%20the%20cerebral%20mechanisms%20underlying%20this%20effect%20have%20never%20been%20investigated.%5CnOBJECTIVE%3A%20To%20assess%20whether%20modulation%20of%20spasticity%20induced%20by%20iTBS%20is%20underlined%20by%20functional%20reorganization%20of%20the%20primary%20motor%20cortices.%5CnMETHODS%3A%20A%20total%20of%2017%20patients%20with%20MS%20suffering%20from%20lower%20limbs%20spasticity%20were%20randomized%20to%20receive%20real%20iTBS%20or%20sham%20iTBS%20during%20the%20first%20half%20of%20a%205-week%20indoor%20rehabilitation%20programme.%20Spasticity%20was%20assessed%20using%20the%20Modified%20Ashworth%20Scale%20and%20the%20Visual%20Analogue%20Scale%20at%20baseline%2C%20after%20the%20stimulation%20session%20and%20at%20the%20end%20of%20the%20rehabilitation%20programme.%20Resting-state%20functional%20magnetic%20resonance%20imaging%20%28fMRI%29%20was%20performed%20at%20the%20three%20time%20points%2C%20and%20brain%20functional%20networks%20topology%20was%20analysed%20using%20graph-theoretical%20approach.%5CnRESULTS%3A%20At%20the%20end%20of%20stimulation%2C%20improvement%20of%20spasticity%20was%20greater%20in%20real%20iTBS%20group%20than%20in%20sham%20iTBS%20group%20%28%20p%5Cu2009%3D%5Cu20090.026%29.%20iTBS%20had%20a%20significant%20effect%20on%20the%20balance%20of%20the%20connectivity%20degree%20between%20the%20stimulated%20and%20the%20homologous%20primary%20motor%20cortex%20%28%20p%5Cu2009%3D%5Cu20090.005%29.%20Changes%20in%20inter-hemispheric%20balance%20were%20correlated%20with%20improvement%20of%20spasticity%20%28rho%5Cu2009%3D%5Cu20090.56%2C%20p%5Cu2009%3D%5Cu20090.015%29.%5CnCONCLUSION%3A%20This%20longitudinal%20resting-state%20fMRI%20study%20evidences%20that%20functional%20reorganization%20of%20the%20primary%20motor%20cortices%20may%20underlie%20the%20effect%20of%20iTBS%20on%20spasticity%20in%20MS.%22%2C%22date%22%3A%2205%202017%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1177%5C%2F1352458516661640%22%2C%22ISSN%22%3A%221477-0970%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%227JR7EDKF%22%2C%22UP3H3ICX%22%2C%22B4EWFM7E%22%2C%22P66W67T8%22%2C%22NF6MTH8W%22%2C%225P5FWCR9%22%2C%226KPLZTET%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A00%3A33Z%22%7D%7D%5D%7D
Stellmann, J.-P., Maarouf, A., Nicolescu, M., Boutiere, C., Rico, A., Zaaraoui, W., Guye, M., Pelletier, J., Ranjeva, J.-P. and Audoin, B. (2025) “Early structural hub disruption leads to premature functional adaption in multiple sclerosis,” Brain Structure & Function, 230(9), p. 172. Available at: https://doi.org/10.1007/s00429-025-03023-2.
Demortiere, S., Stolowy, N., Perriguey, M., Boutiere, C., Rico, A., Hilezian, F., Ndjomo-Ndjomo, B.-R., Durozard, P., Stellmann, J.-P., Marignier, R., Boucraut, J., Pelletier, J., Maarouf, A. and Audoin, B. (2025) “Diagnostic Utility of Kappa Free Light Chain Index in Adults With Inaugural Optic Neuritis,” Neurology(R) Neuroimmunology & Neuroinflammation, 12(3), p. e200386. Available at: https://doi.org/10.1212/NXI.0000000000200386.
Guttieres, L., Vannelli, L., Demortiere, S., Perriguey, M., Elziere, M., Durozard, P., Boutiere, C., Rico, A., Hilezian, F., Stellmann, J.-P., Pelletier, J., Maarouf, A., Stolowy, N. and Audoin, B. (2025) “Fluorescein Angiography as a Surrogate Marker of Disease Activity in Susac Syndrome,” Neurology(R) Neuroimmunology & Neuroinflammation, 12(2), p. e200379. Available at: https://doi.org/10.1212/NXI.0000000000200379.
Durozard, P., Maarouf, A., Zaaraoui, W., Stellmann, J.-P., Boutière, C., Rico, A., Demortière, S., Guye, M., Le Troter, A., Dary, H., Ranjeva, J.-P., Audoin, B. and Pelletier, J. (2024) “Cortical Lesions as an Early Hallmark of Multiple Sclerosis: Visualization by 7 T MRI,” Investigative Radiology, 59(11), p. 747. Available at: https://doi.org/10.1097/RLI.0000000000001082.
Maarouf, A., Stellmann, J.P., Rico, A., Boutiere, C., Demortiere, S., Durozard, P., Zaaraoui, W., Ranjeva, J.-P., Pelletier, J. and Audoin, B. (2024) “Active and non-active progression independent of relapse activity within the first 20 years of relapsing multiple sclerosis,” Journal of Neurology, Neurosurgery, and Psychiatry, p. jnnp-2024-333597. Available at: https://doi.org/10.1136/jnnp-2024-333597.
Graille-Avy, L., Boutiere, C., Rigollet, C., Perriguey, M., Rico, A., Demortiere, S., Durozard, P., Hilezian, F., Vely, F., Bertault-Peres, P., Pelletier, J., Maarouf, A. and Audoin, B. (2024) “Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis,” Neurology(R) Neuroimmunology & Neuroinflammation, 11(3), p. e200231. Available at: https://doi.org/10.1212/NXI.0000000000200231.
Demortiere, S., Joubert, B., Benaiteau, M., Hilezian, F., Boutiere, C., Rico, A., Stolowy, N., Dubois, V., Audoin, B., Maarouf, A. and Pelletier, J. (2024) “Anti-IgLON5 Disease With Inaugural Bilateral Neuropapillitis,” Neurology, 102(8), p. e209284. Available at: https://doi.org/10.1212/WNL.0000000000209284.
Cruz, E.S., Fortanier, E., Hilezian, F., Maarouf, A., Boutière, C., Demortière, S., Rico, A., Delmont, E., Pelletier, J., Attarian, S. and Audoin, B. (2024) “Factors affecting the topography of nitrous oxide-induced neurological complications,” European Journal of Neurology, p. e16291. Available at: https://doi.org/10.1111/ene.16291.
Venet, M., Lepine, A., Maarouf, A., Biotti, D., Boutiere, C., Casez, O., Cohen, M., Durozard, P., Demortière, S., Giorgi, L., Maillart, E., Mathey, G., Mazzola, L., Rico, A., Camdessanche, J.-P., Deiva, K., Pelletier, J. and Audoin, B. (2024) “Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis,” Multiple Sclerosis (Houndmills, Basingstoke, England), p. 13524585231223069. Available at: https://doi.org/10.1177/13524585231223069.
Claverie, R., Perriguey, M., Rico, A., Boutiere, C., Demortiere, S., Durozard, P., Hilezian, F., Dubrou, C., Vely, F., Pelletier, J., Audoin, B. and Maarouf, A. (2023) “Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?,” Neurology(R) Neuroimmunology & Neuroinflammation, 10(5), p. e200152. Available at: https://doi.org/10.1212/NXI.0000000000200152.
Demortiere, S., Maarouf, A., Rico, A., Boutiere, C., Hilezian, F., Durozard, P., Pelletier, J. and Audoin, B. (2023) “Disease Evolution in Women With Highly Active MS Who Suspended Natalizumab During Pregnancy vs Rituximab/Ocrelizumab Before Conception,” Neurology(R) Neuroimmunology & Neuroinflammation, 10(5), p. e200161. Available at: https://doi.org/10.1212/NXI.0000000000200161.
Maarouf, A., Audoin, B., Gherib, S., El Mendili, M.M., Viout, P., Pariollaud, F., Boutière, C., Rico, A., Guye, M., Ranjeva, J.-P., Zaaraoui, W. and Pelletier, J. (2022) “Grey-matter sodium concentration as an individual marker of multiple sclerosis severity,” Multiple Sclerosis Journal, 28(12), pp. 1903–1912. Available at: https://doi.org/10.1177/13524585221102587.
Poullet, Z., Pique, J., Maarouf, A., Boutiere, C., Rico, A., Demortiere, S., Durozard, P., Papeix, C., Maillart, E., Collongues, N., Ayrignac, X., Zephir, H., Deschamps, R., Ciron, J., Pelletier, J., Marignier, R. and Audoin, B. (2022) “Pure Relapsing Short Myelitis: Part of the Multiple Sclerosis Spectrum or New Entity?,” Neurology(R) Neuroimmunology & Neuroinflammation, 9(4), p. e1167. Available at: https://doi.org/10.1212/NXI.0000000000001167.
Perriguey, M., Maarouf, A., Stellmann, J.-P., Rico, A., Boutiere, C., Demortiere, S., Durozard, P., Pelletier, J. and Audoin, B. (2022) “Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab,” Neurology(R) Neuroimmunology & Neuroinflammation, 9(1), p. e1115. Available at: https://doi.org/10.1212/NXI.0000000000001115.
Rico, A., Ninove, L., Maarouf, A., Boutiere, C., Durozard, P., Demortiere, S., Saba Villarroel, P.M., Amroun, A., Fourié, T., de Lamballerie, X., Pelletier, J. and Audoin, B. (2021) “Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy,” Multiple Sclerosis Journal - Experimental, Translational and Clinical, 7(4), p. 20552173211062142. Available at: https://doi.org/10.1177/20552173211062142.
Hilezian, F., Maarouf, A., Boutiere, C., Rico, A., Demortiere, S., Kerschen, P., Sene, T., Bensa-Koscher, C., Giannesini, C., Capron, J., Mekinian, A., Camdessanché, J.-P., Androdias, G., Marignier, R., Collongues, N., Casez, O., Coclitu, C., Vaillant, M., Mathey, G., Ciron, J., Pelletier, J. and Audoin, B. (2021) “TNF-α inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosis,” Journal of Neurology, Neurosurgery & Psychiatry, 92(8), pp. 890–896. Available at: https://doi.org/10.1136/jnnp-2020-325665.
Perez, T., Rico, A., Boutière, C., Maarouf, A., Roudot, M., Honoré, S., Pelletier, J., Bertault-Peres, P. and Audoin, B. (2021) “Comparison of rituximab originator (MabThera®) to biosimilar (Truxima®) in patients with multiple sclerosis,” Multiple Sclerosis (Houndmills, Basingstoke, England), 27(4), pp. 585–592. Available at: https://doi.org/10.1177/1352458520912170.
Demortiere, S., Rico, A., Maarouf, A., Boutiere, C., Pelletier, J. and Audoin, B. (2020) “Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis,” Multiple Sclerosis (Houndmills, Basingstoke, England), p. 1352458520912637. Available at: https://doi.org/10.1177/1352458520912637.
Durozard, P., Rico, A., Boutiere, C., Maarouf, A., Lacroix, R., Cointe, S., Fritz, S., Brunet, C., Pelletier, J., Marignier, R. and Audoin, B. (2020) “Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases,” Annals of Neurology, 87(2), pp. 256–266. Available at: https://doi.org/10.1002/ana.25648.
Maarouf, A., Rico, A., Boutiere, C., Perriguey, M., Demortiere, S., Pelletier, J., Audoin, B. and Under the aegis of OFSEP (2020) “Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?,” Neurology - Neuroimmunology Neuroinflammation, 7(5), p. e825. Available at: https://doi.org/10.1212/NXI.0000000000000825.
Touati, J., Rico, G., Habert, P., Gérault, M., Gaubert, J.Y., Chagnaud, C. and Varoquaux, A. (2020) “Prevention of nosocomial transmission of SARS-CoV-2 using pre-operative chest CT: a monocentric study during the outbreak,” The Journal of Hospital Infection, 106(1), pp. 186–188. Available at: https://doi.org/10.1016/j.jhin.2020.07.005.
Melenotte, C., Loukil, A., Rico, A., Lepidi, H. and Raoult, D. (2019) “Blood Culture–Negative Cardiovascular Infection in a Patient With Multiple Sclerosis,” Open Forum Infectious Diseases, 6(10), p. ofz429. Available at: https://doi.org/10.1093/ofid/ofz429.
De Looze, C., Moreau, N., Renié, L., Kelly, F., Ghio, A., Rico, A., Audoin, B., Viallet, F., Pelletier, J. and Petrone, C. (2019) “Effects of cognitive impairment on prosodic parameters of speech production planning in multiple sclerosis,” Journal of Neuropsychology, 13(1), pp. 22–45. Available at: https://doi.org/10.1111/jnp.12127.
Maarouf, A., Boutière, C., Rico, A., Audoin, B. and Pelletier, J. (2018) “How much progress has there been in the second-line treatment of multiple sclerosis: A 2017 update,” Revue Neurologique, 174(6), pp. 429–440. Available at: https://doi.org/10.1016/j.neurol.2018.01.369.
Meunier, B., Rico, A., Seguier, J., Boutiere, C., Ebbo, M., Harle, J.R., Schleinitz, N. and Pelletier, J. (2018) “Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab,” Multiple Sclerosis Journal, 24(6), pp. 811–813. Available at: https://doi.org/10.1177/1352458517729766.
Doche, E., Lecocq, A., Maarouf, A., Duhamel, G., Soulier, E., Confort-Gouny, S., Rico, A., Guye, M., Audoin, B., Pelletier, J., Ranjeva, J.-P. and Zaaraoui, W. (2017) “Hypoperfusion of the thalamus is associated with disability in relapsing remitting multiple sclerosis,” Journal of Neuroradiology. Journal De Neuroradiologie, 44(2), pp. 158–164. Available at: https://doi.org/10.1016/j.neurad.2016.10.001.
Maarouf, A., Audoin, B., Pariollaud, F., Gherib, S., Rico, A., Soulier, E., Confort-Gouny, S., Guye, M., Schad, L., Pelletier, J., Ranjeva, J.-P. and Zaaraoui, W. (2017) “Increased total sodium concentration in gray matter better explains cognition than atrophy in MS,” Neurology, 88(3), pp. 289–295. Available at: https://doi.org/10.1212/WNL.0000000000003511.
Grimaldi-Bensouda, L., Rossignol, M., Koné-Paut, I., Krivitzky, A., Lebrun-Frenay, C., Clet, J., Brassat, D., Papeix, C., Nicolino, M., Benhamou, P.-Y., Fain, O., Costedoat-Chalumeau, N., Courcoux, M.-F., Viallard, Jean-François, Godeau, B., Papo, T., Vermersch, P., Bourgault-Villada, I., Breart, G., Abenhaim, L., Abbas, F., Abdelmoumni, A., Hilliquin, P., Requeda, E., Adoue, D., Brassat, D., Agard, C., Masseau, A., Aladjidi, N., Clet, J., Fernandes, H., Lemasson, G., Perel, Y., Raymond, I., Richer, O., Vital, A., Allain-Launay, E., Bru, M., Nicolino, M., Thomas, C., Altman, J.-J., Amsallem, D., Aras, N., Boukari, L., Dubrel, M., Fain, O., Letellier, E., Lucidarme, N., Mekinian, A., Morin, A.-S., Stirnemann, J., Atlan, C., Audry, D., Augustin, J., Bakir, R., Bartolucci, P., Chevalier, X., Godeau, B., Guillaud, C., Khellaf, M., Limal, N., Lousteau, V., Mahevas, M., Méliksetyan, G., Michel, M., Roumier, M., Bayart, S., Bonnet, F., Decaux, O., Bekherraz, A., Brihaye, B., Dachez, R., Daugas, E., Hayem, G., Meyer, O., Papo, T., Pasqualoni, E., Sacre, K., Travert, F., Bellon, H., Beltrand, J., Lefrere, F., Simon, A., Benhamou, P.-Y., Benveniste, O., Bolgert, F., Costedoat-Chalumeau, N., De Paz, R., Demeret, S., Fautrel, B., Jacqueminet, S., Louapre, C., Maillart, E., Morel, N., Papeix, C., Rigabert, J., Bensaid, P., Berger, C., Berquin, P., Le Moing, A.-G., Berroir, S., Besson, G., Boutte, C., Casez, O., Bonnotte, B., Audia, S., Bossu-Estour, C., Bourgarit, A., Dupuy, A., Keshmandt, H., Bourre, B., Brac, A., Perrin, A., Pondarré, C., Villar-Fimbel, S., Bruckert, I., Cosson, A., Magy-Bertrand, N., Tisserand, G., Camu, W., Carlander, B., Morales, R.J., Cances, C., Pasquet, M., Castilla Lievre, M.A., Chabroux, S., Charif, M., Chatelus, E., Sibilia, J., Chevrant-Breton, J., Clavel, S., Bille-Turc, F., Cohen, J., Courcoux, M.F., Leverger, G., Machet, L., Cuisset, J.-M., Cony-Makhoul, P., Darsy, P., Favre, S., Giraud, P., Leitenschenck, L., Monteiro, I., Morati, C., DeSeze, J., Dinulescu, M., Dhaoui, T., Dommange-Romero, F., Drevard, E., Dupuis, C., Dumuis, M.-L., Durand, J.-M., Farad, S., Lecomte, P., Pierre, P., Fouyssac, F., Gaudin, P., Gautier, A., Gellen-Dautremer, J., Jarrin, I., Richette, P., Georget, E., Gras, P., Moreau, T., Giraud, E., Hacini, M., Mayer, A., Guillaumat, C., Guillaume, S., Guitton, C., Kone-Paut, I., Marsaud, C., Rossi, L., Guyot, M.-H., Hassler, P., Heimfert, C., Heinzlef, O., Hillion, B., Hocquelet, C., Husson, H., Ichai, P., Jeziorski, E., Deslandre, C.J., Le Guern, V., Kamenov, K., Kerlan, V., Lemoine, P., Misery, L., Pan-Petesch, B., Krivitzky, A., Labauge, P., Rodier, M., Lacade, C., Razafimahefa, B., Lachgar, K., Larmarau, M.-P., Leblanc, T., Lebrun-Frenay, C., Lefèbvre, P., Lejoyeux, P., Leske, C., Ly, K., Magy, L., Mansuy, S., Marechaud, R., Martin Negrier, M.-L., Sole, G., Maupetit, J., Mazingue, F., Mochon, S., Moktar, B., Morcamp, D., Morlet-Barla, N., Nicolas, G., Pautot, V., Pellier, I., Verret, J.-L., Outteryck, O., Vermersch, P., Pallot-Prades, B., Paquet, J.M., Puechal, X., Sortais, A., Pelletier, J., Rico, A., Pez, D., Stankoff, B., Quittet, P., Rémy, C., Roba, E., Rosario, H., Roudaut, N., Sonnet, E., Ruel, M., Sebban, S., Schaepelynck, P., Simonin, M.-J., Vial, C., Viallard, Jean-Francois, Ladedan, I. and Zenone, T. (2017) “Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance,” Journal of Autoimmunity, 79, pp. 84–90. Available at: https://doi.org/10.1016/j.jaut.2017.01.005.
Maillart, E., Vidal, J.-S., Brassat, D., Stankoff, B., Fromont, A., de Sèze, J., Taithe, F., Clavelou, P., Bourre, B., Delvaux, V., Rico, A., Labauge, P., Tourbah, A., Lebrun, C., Pelletier, J., Moreau, T., Louapre, C., Lubetzki, C. and Papeix, C. (2017) “Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome,” Neurology - Neuroimmunology Neuroinflammation, 4(3), p. e346. Available at: https://doi.org/10.1212/NXI.0000000000000346.
Boutière, C., Rey, C., Zaaraoui, W., Le Troter, A., Rico, A., Crespy, L., Achard, S., Reuter, F., Pariollaud, F., Wirsich, J., Asquinazi, P., Confort-Gouny, S., Soulier, E., Guye, M., Pelletier, J., Ranjeva, J.-P. and Audoin, B. (2017) “Improvement of spasticity following intermittent theta burst stimulation in multiple sclerosis is associated with modulation of resting-state functional connectivity of the primary motor cortices,” Multiple Sclerosis (Houndmills, Basingstoke, England), 23(6), pp. 855–863. Available at: https://doi.org/10.1177/1352458516661640.